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Thesis abstract
Listeria monocytogenes is a foodborne pathogen, which continues to be
problematic to the food industry due to its ability survive within food products and persist
within food processing environments. The growing trend towards natural food preservatives
and antimicrobial agents increases the need for the development of novel, natural anti-Listeria
agents. Evidence presented in the literature suggests that the human gut microbiota is a
reservoir of novel antimicrobial agents. It was therefore hypothesized that novel anti-Listeria
agents are produced by human gut-derived bacteria. The objective of this study was to isolate
and characterize gut bacteria with anti-Listeria monocytogenes activity.
A total of 23 fecal banks of human origin were screened for antagonistic activity
against L. monocytogenes 10403S. The results of the initial screening have shown that 1,569
gut-derived isolates have demonstrated various levels of anti-Listeria activity. Following an
extensive screen 59 gut-derived isolates were initially shortlisted and were identified mostly as
Enterococcus spp. By a combination of MALDI-TOF MS analysis and 16S rRNA gene
sequencing. The data collected allowed a further shortlisting of strains from 59 to 16 based on
differences observed in the colony morphology, the size and appearance of the zones of
inhibition observed in the deferred antagonism assays and well diffusion assays as well as
spectrum of activity of each isolate against a number of indicator strains. The antimicrobials
produced by 11 out of 16 shortlisted gut derived isolates were identified as peptides using a
proteinase K assay. The anti-Listeria activity of the shortlisted isolates was examined in a
model broth co-culture experiment. Based on the results obtained the antimicrobials produced
by two Enterococcus faecium isolates were selected for further investigation. The activity of
the antimicrobials was investigated in dairy food homogenate models and stainless steel
biofilm assays. The findings of the food trials have shown a reduction of Listeria numbers by
~0.6 Log CFU/mL in natural yogurt treated with cell free supernatant (CFS) and a reduction
of ~1.5 log CFU/mL observed in cheddar cheese treated with whole cell extract (WCE)
following a 3 hr incubation. The anti-biofilm assays demonstrated a reduction in biofilm
formation of stainless steel by 70% when treated with CFS and 92.42% when treated with
WCE.

iv

The experiments presented in this thesis confirm that bacteria from the human gut
produce anti-Listeria compounds which can control or reduce the numbers of Listeria in model
co-cultures and in food homogenates. The antimicrobials isolated in this study have also shown
the ability to reduce Listeria biofilm formation. Future efforts should focus on identifying the
antimicrobials produced by all of the short-listed strains (through a combination of genome
sequencing and peptide purifications). It is hoped that any novel antimicrobial that is
discovered have an application in the food industry to reduce the significant threat posed by
L. monocytogenes. These antimicrobials could be used as a natural preservative in food
products or packaging or incorporated into a spray to control biofilm in the food processing
environment.

v

Literature review

Inhibition of Listeria monocytogenes by human gut bacteria

1

Contents
1. Introduction

3

2. Listeria monocytogenes

3

2.1 Pathogenicity of L. monocytogenes

4

2.2 Outbreaks of listeriosis

6

2.3 Stress tolerance and persistence in the food industry

8

2.4 Listeria biofilms

10

3. Human gut microbiota

12

3.1 Cultivation of gut microbiota

13

3.2 Metagenomics and 16S sequencing to identify microbes in
the gut-microbiota

14

3.3 Functions of the gut microbiota
4 Antimicrobials produced by the gut bacteria

16
18

4.1 Non-peptide antimicrobials produced by gut bacteria

21

4.1.1 Short chain fatty acids (SCFAs)

21

4.2 Antimicrobial peptides produced by gut bacteria

23

4.2.1 Bacteriocins

24

4.3 Identification of antimicrobials from the gut

30

5 Evidence that gut microbiota inhibits Listeria

32

6 Conclusions and future directions

35

2

1. Introduction
L. monocytogenes is a causative agent of a severe foodborne disease;
listeriosis (Mead et al. 1999; Scallan et al. 2011). The disease is particularly dangerous
for immunocompromised individuals, the elderly and pregnant women. Despite a
relatively low number of outbreaks the mortality rate is high reaching 30% and is
accountable for 16-28% of foodborne disease related deaths in the US annually (Mead
et al. 1999; Scallan et al. 2011). The pathogen is very problematic especially in the
food industry where it can survive various processing hurdles such as extreme
temperature, pH, or osmotic pressure (Hill et al. 2002). Additionally the bacterium is
capable of biofilm formation (section 2.4), which makes its eradication even more
difficult and allows for its persistence in the food processing environment and
contamination of food products (Bagge-Ravn et al. 2003; Gunduz & Tuncel 2006;
Sharma & Anand 2002). Novel approaches / methods to inhibit and control L.
monocytogenes are urgently required.
The human gut microbiome is home to approximately 1014 bacteria (Gill et
al. 2006), which provide protection to the host by a mechanism known as colonization
resistance. Direct competition for nutrients, production of short chain fatty acids or
bacteriocins as well as modulation of the host immune system can all inhibit gut
colonization by enteric pathogens (Kamada et al 2013). This review provides an
overview of some of the antimicrobials produced by gut bacteria and it summarizes the
evidence that shows that gut bacteria can inhibit L. monocytogenes.

2. Listeria monocytogenes
L. monocytogenes is a Gram-positive, non-spore forming facultative
anaerobe (Jamali et al. 2013; Zhang et al. 2007). Murray et al. (1926) were first to
describe L. monocytogenes when the pathogen was isolated from infected rabbits. For
years L. monocytogenes was regarded as an animal pathogen as human infections with
the bacterium were sporadic. Schlech et al. (1983) linked the transmission of the
pathogen to food. Since its discovery Listeria has been extensively researched which
makes it one of the best-characterized pathogens (Cossart 2007; Lebreton et al. 2016).
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2.1 Pathogenicity of L. monocytogenes
L. monocytogenes is highly infectious when ingested with an infectious dose of 1001,000 cells (Almeida et al. 2013; Drevets and Bronze, 2008; Zhang et al. 2007).
Outbreaks are mostly associated with transmission via food (Carpentier & Cerf 2011).
Pregnant women, infants, elderly and immunocompromised people belong to the most
susceptible group and are under increased risk of developing listeriosis upon
consumption of contaminated food (Jamali et al. 2013). Despite the fact that the
foodborne disease listeriosis caused by L. monocytogenes is not as frequent as those
associated with Salmonella or Campylobacter its high mortality makes it a pathogen of
high concern to the food industry (Donovan 2015; Mead et al. 1999) L. monocytogenes
can have a long incubation period especially in pregnant women (Goulet et al. 2013),
which makes it problematic not only to identify the pathogen, but also to trace the
source of infection. Septicaemia, meningitis and various infections of the central
nervous system are often associated with listeriosis. The disease is particularly severe
in pregnant women where it may cause complications such as spontaneous abortion,
foetal death or stillbirth (Rocourt & Cossart 1997).
Infection with L. monocytogenes can cause serious consequences to the
host, depending on their susceptibility. Severity can vary from infections of the central
nervous system and /or blood stream, gastroenteritis, abortion, brain infections or
materno-foetal infections (Carpentier & Cerf 2011; Toledo-Arana et al. 2009). The
disease can also take the form of severe listeriosis (Almeida et al. 2013; Carpentier &
Cerf 2011; Gilbreth et al. 2005). Listeria’s ability to cause disease relies on a number
of factors. Those include its capability to attach and invade the gastrointestinal
epithelium as well as the ability to withstand the immune response of the host (Corr et
al. 2007). Although the topic is extensively researched, the behavior of the pathogen
once it invades the gastrointestinal tract is not fully known (Corr et al. 2007).
L. monocytogenes has 13 known serotypes, but it has been estimated that
>50% causes of listeriosis are caused by strains with serotype 4b and that the majority
of strains isolated from food are strains of serotype 1/2a (Gilbreth et al. 2005). One
factor which allows L. monocytogenes to adapt to various hurdles inside the human
body, is its ability to withstand a wide range of pH changes from pH 4.6 to pH 9.5
4

which enables it to survive during gastric passage (Carpentier & Cerf 2011; Almeida
et al. 2013; Gandhi & Chikindas 2007). L. monocytogenes is also known for being able
to survive the environmental conditions found in the human immune system (Hill et al.
2002; Mead et al. 1999) and is highly osmotolerant as it can endure NaCl
concentrations of 10-20% (w/v) and has the ability to withstand water activity of 0.92
(Carpentier & Cerf 2011). It is believed that L. monocytogenes ability to adapt to
changing environmental factors aided by assimilation of the information about the
external environment to which the bacterium is exposed (Hill et al. 2002; Mead et al.
1999).
It is estimated that ingestion of less than 1,000 cells of L. monocytogenes
can cause infection in people belonging to the susceptible group (Drevets and Bronze,
2008). When ingested the bacterial cells infect the gastro-intestinal epithelium and
becomes blood borne, the bacterium can then infect the spleen, liver and the lymphatic
system (Drevets and Bronze, 2008). It can then invade the nervous system; in the case
of pregnant women it can cross over the placental barrier and infect the foetus.
Listeriosis has a high fatality and hospitality rates however it can be treated with
antibiotics if detected early (Williams and Nadel, 2001). Typically listeriosis is treated
with a combination of antibiotics including penicillin and ampicillin combined with
gentamicin (Hof et al. 1997; Marco et al. 2000; Safdar and Amstrong 2003).
As described by Vázquez-Boland et al. (2001) the clinical consequence of
infection with L. monocytogenes is highly dependent on three main variable conditions.
Those include; the ingested dose of the pathogen, the pathogenicity of the ingested
strain of Listeria and the immunological health of the infected individual. It is believed
that ingestion of a low dose of L. monocytogenes by an individual who is
immunocompetent and does not fall into the susceptibility group should have no
adverse effects on their health other than increasing anti-Listeria immunity. However
ingestion of a high dose of the bacterium can be harmful and may result in fever,
gastroenteritis and potentially an invasive infection. In contrast immunocompromised
and fatigued individuals cannot display an immune response powerful enough to limit
the propagation of the pathogen in the liver, which is the main organ associated with L.
monocytogenes infection. As a consequence those individuals are susceptible to
development of an invasive Listeria infection even at a lower dose. Additionally an
unsuccessful reduction of L. monocytogenes growth in the liver cells in those
5

individuals is likely to result in an increased critical mass of the bacterium present in
the hepatocytes and subsequent release of bacterial cells into the blood stream.
Furthermore this can result in local infections of the main secondary organs associated
with Listeria infections such as the placenta and the brain, in critically
immunocompromised individuals the infection can become septicemic (VázquezBoland et al. 2001). The pathophysiology of L. monocytogenes infection is shown in
Fig.1.

Fig.1 A schematic representation of the pathophysiology of Listeria infection. (Figure
taken from Vázquez-Boland et al. 2001).

2.2. Outbreaks of listeriosis
There are a number of factors which can impact the prevalence of L.
monocytogenes and listeriosis outbreaks; those include the globalization of the food
industry and growing need for imported ethnic foods. The evolution of eating habits
leaning towards consumption of minimally processed food and an increased demand
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for refrigerated and ready to eat convenience foods all affect the occurrence of
listeriosis outbreaks in recent years (Rocourt and Bille, 1997). The foods commonly
associated with Listeria outbreaks are soft cheese and other dairy based foods such
as Latin style fresh cheese or Mexican style cheese, smoked fish, pates, hot-dogs,
fresh vegetable and ready to eat foods (de Castro et al. 2012; FDA 2017; Gillesberg
Lassen et al. 2016; Jackson et al. 2018; Morris & Ribeiro 1991; Pinto et al. 2010;
Ricci et al. 2018; Schwartz et al. 1988; Zhu et al. 2017). The common feature of
these food products, which makes them favourable for the pathogen growth are the
intrinsic properties of those products. Those include moderate water activity and
reasonably low microflora which can survive in the storage conditions of such food
products and can compete with Listeria (Swaminathan and Gerner-Smidt, 2007).
Some of the more recent listeriosis outbreaks include four state outbreak in the US
linked to raw milk cheese, which caused 8 hospitalizations and 2 deaths and resulted
in recall of the product (CDC 2017). Another smaller outbreak was caused by raw
organic milk contaminated with L. monocytogenes where 2 people from 2 different
states were hospitalized and one mortality was recorded, there was no recalls of the
contaminated product associated with the outbreak as the causative agent of the
foodborne disease was not recognized until 2 years later (CDC 2016). Makino et al.
(2005) reported an outbreak of L. monocytogenes associated with consumption of
cheese. In this case 86 people were infected with the pathogen and 38 developed
clinical symptoms associated with listeriosis, it was the first reported case of
listeriosis outbreak in Japan. Koch et al. (2010) described an outbreak reported in
Germany where 189 individuals were infected with L. monocytogenes due to
consumption of contaminated cheese made with pasteurized milk. One of the largest
Listeria outbreaks ever recorded took place in South Africa between the January of
2017 and March of 2018. There has been 978 confirmed cases of listeriosis and 183
reported deaths. The outbreak has been linked to a ready to eat sausage product.
Listeria monocytogenes Sequence Type 6 (ST6) has been determined as the main
contaminant found in the food processing plants, however 9% of listeriosis reported
have been associated with a different strain of Listeria suggesting multiple
outbreaks. Further investigations are ongoing (“WHO Listeriosis – South Africa,”
2018).
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Despite continuous advances in food technology the changing food trends
are shifting towards less processed ready to eat products. Additionally changes in the
life spans of the older, more susceptible population group mean that L. monocytogenes
amongst other foodborne pathogens will remain an issue to the food industry (Begley
and Hill 2015; Newell 2010).

2.3 Stress tolerance and persistence in the food industry
L. monocytogenes is capable of survival and growth over a wide range of
environmental conditions with a broad scope of temperatures ranging from 1-45 °C.
Additionally it has the ability to survive and grow at refrigeration temperatures (1-4°C)
which make it very problematic to control its growth in food products, bearing in mind
that refrigeration is one of the most common methods used for shelf life extension for
many food products (Almeida et al. 2013; Carpentier & Cerf 2011).
L. monocytogenes is often found in the environment with important sources
of the bacterial contamination including water and soil. The survival of the pathogen in
soil can be affected by a number of factors including presence of competing microbiota
and the composition of the soil. Additionally its persistence in the environment can be
affected by weather (NicAogáin & O’Byrne 2016; Swaminathan & Gerner-Smidt
2007). Exposure to contaminated feed can then infect the animals, which shed the
bacterium in their faeces (Swaminathan and Gerner-Smidt, 2007). The bacterium can
then further spread to the environment and contaminate crops when animal manure
containing Listeria is spread onto fields as a fertilizer (Schlech et al. 1983; Szymczak
et al. 2014). Resulting contaminated animal or plant material can introduce the
bacterium into food processing plants where undetected it can grow to high numbers
and can potentially contaminate food product even post processing (Guerini et al. 2007;
Leong et al. 2014). The bacterium can then enter the food chain and infect consumers
(NicAogáin & O’Byrne 2016). A schematic of transition of L. monocytogenes from the
agricultural environment to the food chain is depicted in Fig.2 below.
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Fig. 2 The survival and transmission of Listeria monocytogenes in the agricultural
environment, the food industry and its subsequent entry of the food chain (This figure
was taken from NicAogáin & O’Byrne 2016).
A number of studies have been performed within food processing
environments, the data collected in those studies shows that the occurrence of L.
monocytogenes within those environments can be either endemic or transient
(Carpentier & Cerf 2011; Martinez et al. 2003; Norton et al. 2001; Rørvik et al. 2003).
The transient or passing populations of Listeria are often introduced to the food
processing environments on contaminated raw materials such as raw meat and are often
depleted once the source of contamination is gone. The endemic, more persistent
Listeria populations can develop on surfaces and may come in contact with the food
product, examples of such contact surfaces include conveyer belts or slicers (Klausner
& Donnelly 1991; Scollon et al. 2016).

Scollon et al. (2016) reported cross-

contamination of raw onions with L. monocytogenes from slicers used for product
preparation. The contaminated product was linked to a number of recalls of products
containing contaminated onion. Listeria was also reported to attach to surfaces with
poor hygiene such as drainage areas, storage areas and walls as reported by Gunduz &
Tuncel (2006). Once established in a food processing environment Listeria populations
can form biofilms and persist for prolonged periods of time as reported by Unnerstad
et al. (1996) who recovered the same clone of L. monocytogenes from Scandinavian
dairy and cheese manufacturing plant over a period of 7 years.
9

Hilliard et al. (2018) compared a selection of 1,300 Irish L. monocytogenes
isolates from food processing environments and food samples and used pulse-field gel
electrophoresis and whole genome sequencing methods in order to compare the
genomes of those isolates to 25 clinical isolates associated with outbreaks of listeriosis
in Ireland during time period for 2013 to 2015. The study has found that 64% of the
clinical pulsotypes of isolates were previously identified in food or in the food
processing environments. Additionally the genomes of five matching isolates were
sequenced and revealed correlations between the genotypes and the pulsotypes of the
isolates. The findings of the study show that there are close similarities in the L.
monocytogenes strains currently responsible for infections with listeriosis and the
isolates found in the food environment suggesting that contamination of food products
associated with the disease is potentially caused by endemic populations of L.
monocytogenes found in the food industry.

2.4 Listeria biofilms
Some bacteria are able to form biofilm (i.e. embed themselves in a selfproduced polymer matrix) that allows adherence to biotic or abiotic surfaces. Biofilms
can arise in nearly any environment where the viable microorganism capable of biofilm
formation is present (Kumar and Anand, 1998). Biofilms are of concern to the food
industry as they frequently contain pathogenic bacteria, which increases the risk of
post-processing contamination of the product and subsequent product spoilage while
posing a serious threat to the public health (Shi & Zhu 2009; Singh et al. 2017). A
number of studies have shown that that formation of biofilm in food industry settings
is one of the key factors contributing to post processing product contamination (BaggeRavn et al. 2003; Gunduz & Tuncel 2006; Sharma & Anand 2002).
Biofilms can be found on a broad range of surfaces including water system
piping, equipment, stainless steel surfaces, conveyer belts and storage areas and storage
tanks, floor drains and hand trucks (Di Bonaventura et al. 2008; Donlan 2002; Kumar
& Anand 1998; Mafu et al. 1990; Wong 1998).
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Listeria biofilms often display an increased resistance to disinfectants,
sanitizers and other antimicrobial agents, which makes their elimination a challenging
task for the food manufacturers (Mah & O’Toole 2001; Lundén et al. 2003; Romanova
et al. 2002). A study by Cabeça et al. (2012) demonstrated that Listeria biofilm is
resistant to cleaning with chemical agents such as iodine disinfectant, biguanide
disinfectant, quaternary ammonium compounds disinfectant, peracetic acid, sodium
hypochlorite disinfectant and can persist on stainless steel. The results of the study are
presented in Fig.3.
Listeria has the ability to form monoculture biofilms as well as mixed
culture biofilm (Bremer et al. 2001). A study carried out by Bremer et al. (2001)
investigated Listeria`s ability to form biofilms in a monoculture and as part of a mixed
culture biofilm with Flavobacterium. The findings of the study showed that when
grown in a mixed culture the number of Listeria a cells attached to stainless steel has
significantly increased when compared to monoculture biofilm. Additionally it was
noted that that the survival period of Listeria cells in the mixed culture biofilm was
significantly longer than that of monoculture biofilm (Bremer et al. 2001). However
some microorganisms found in the food processing environment can have the opposite
effect. A study carried out by Carpentier & Chassaing (2004) focused on isolation of
microorganisms found in 7 various food processing plants following cleaning and
disinfection procedures. A total of 29 bacterial strains were isolated and the isolates
were allowed to form a mixed culture biofilm with Listeria on stainless steel coupons
and the influence of those isolates on the biofilm formation was measured. The data
showed that 16 of the bacterial isolates have in fact reduced the number of CFU of
Listeria found in the biofilm while 4 had a positive impact on biofilm formation
resulting in increased number CFU of Listeria attached to the surface of the stainless
steel coupons (Carpentier and Chassaing, 2004). Findings of such studies are of high
importance to the food industry as many microorganisms and pathogenic bacteria such
as Listeria are often found in various parts of food processing plants where there is an
increased likelihood of formation of mixed culture biofilm.
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Fig. 3 Scanning electron micrograph of L. monocytogenes biofilm on stainless steel
surface (x5,000) (A) biofilm before treatment with disinfectants (B) after treatment with
iodine disinfectant (C) after treatment with biguanide disinfectant (D) after treatment
with quaternary ammonium compounds disinfectant (E) after treatment with peracetic
acid (F) after treatment with sodium hypochlorite disinfectant. (This figure was adapted
from Cabeça et al. 2012).

3.0 Human gut microbiota
The human gut microbiome comprises between 10 13

and 1014

microorganisms (Gill et al. 2006). The gut microbiota is mainly composed of members
of two phyla, namely Firmicutes and Bacteroidetes (Arumugam et al. 2011). In recent
years new advancement in research of culturomics and metagenomics of the human
gut allowed for greater research of the gut microbiome and its functions. Due to its
beneficial functions it has been referred to as an “essential” (Eckburg et al. 2005) or
the “forgotten” organ (O’Hara & Shanahan 2006). A number of studies support the
theory that the gut microbiome has a massive impact on numerous aspect of human
health in areas such as metabolism, immune function, physiology and nutrition (Cénit
et al. 2014; Eckburg et al. 2005; Guinane & Cotter 2013).
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3.1 Cultivation of the gut microbiota
Investigation of the composition and functions of the gut microbiota is a
challenging task. Traditional methods of cultivation of gut microbiota are practically
completely culture dependent. This has provided huge benefits when cultivating so
called “easily grown microbial species” which can grow under lab conditions, however
cultivation of anaerobic species is still very limited. Traditional methods allow for
culturing only 10-50% of the bacteria found in the human gut, which are considered to
be “easy to culture” (Eckburg et al. 2005). Overall cultivation of the majority of the gut
bacteria from what is considered as a “normal” gut, is very ineffective especially when
considering the fact that the understanding of carbon sources necessary for microbial
growth within the gut is very limited and therefore difficult to reproduce within a lab
set up (Cénit et al. 2014; Lagier et al. 2012).
The majority of studies examining the microbial populations of the
gastrointestinal microflora focus predominantly on the analysis of faecal samples as
those are easy to obtain (Atya et al. 2015; Awaisheh et al. 2013; Birri et al. 2010; Birri
et al. 2013). However the structural and functional differences between the mucosal
and faecal micro flora are not fully known (Eckburg et al. 2005). There are a number
of the restrictions associated with the culture based approach, which can to an extent
be overcome due to the recent developments such as of cultivation methods of
microorganisms with more fastidious needs, such developments include microbial
culturomics of the gastrointestinal microflora (Lagier et al. 2016).
Research in the field of cultivation of gut bacteria has led to the
development of new culturing methods combined with the use of matrix–assisted laser
desorption/ionization–time of flight mass spectrometry (MALDI-TOF) and 16S rRNA
gene sequencing for identification and amplification of the growing bacterial colonies
with the aim of identifying previously unidentified organisms. Lagier et al. (2012)
carried out a study on two African stools, where 212 various culture conditions were
investigated including different physicochemical conditions such as pre-incubation in
sterile stool extract, pre-incubation in rumen fluid or pre-incubation in blood, all with
the aim to copy the natural environments for the gut bacteria. This methodology
allowed for recovery of 32,500 colonies which have been identified as 340 bacterial
13

species, 174 of which were previously not described in the human gut. The
methodology used by this approach focused on omission of the microorganisms, which
can be cultured using the traditional culture based approach and are predominant in the
gut. The abundant population of easy to culture organisms were eliminated with the use
of phage cocktails, antibiotics or filtration methods. Elimination of those organisms
allows for supplementary growth of the microbes of interest and allows for their
identification. In more detail antibiotics were added to the culture media in order to
eliminate the sensitive microorganisms present in the samples and allow for
identification of the resistant ones. New approaches were developed in order to advance
the use of “classic selective media”. Alternative strategies were developed in order to
identify the proteobacteria present in the samples, one of the major obstacles
encountered was the fact that under the aerobic condition the population of E. coli was
immensely dominant. In order to overcome that problem and allow for identification of
less abundant microorganisms a cocktail of lytic bacteriophages targeting E. coli was
added to the culture. This allowed for identification of Enterobacter massiliensis, a
previously unknown member of enterobacterial species, which could not be detected
with the use of traditional axenic culture approaches. Other effective strategies which
allowed for the removal of major, dominant bacterial populations present in the samples
was the use of active filtration with successive membranes with pore sizes ranging from
5 to 0.2 lm. This approach identified 8 new bacterial species. The final approach used
focused on exploiting the physical characteristics of some bacteria, passive filtration
was applied and allowed

the identification of 3 motile bacteria previously not

associated with the human gut. The study used MALDI -TOF MS for rapid
identification of colonies, colonies not identified with that approach were identified
with 16S rRNA sequencing (Lagier et al. 2012).

3.2 Metagenomics and 16S rRNA sequencing to identify microbes in the gutmicrobiota.
Metagenomics is defined as a genetic analysis of an entire microbial population
from an environmental sample (Handelsman, 2004). With the aid of bioinformatics and
genomic sequence based studies, metagenomic studies look at all the genes present in
a given environment and can detect novel genes, novel proteins from already known
14

protein families and novel small molecules with antimicrobial activities (Chen &
Pachter 2005; Handelsman 2004; Petrosino et al. 2009). Mammals including humans
are considered metagenomic due to the fact that their composition extends past their
own genetic material and comprises of the genetic material of the microbes associated
with them. This is especially evident when talking about the mammalian
gastrointestinal tract (Ley et al. 2008). It is anticipated that the human gastrointestinal
tract comprises over 2,000 different microbial species and accumulates over 1014
microbial cells the collective microbial genome is estimated to be over 9 million and
its metabolic activity is equivalent to an organ (Bocci 1992; Hugon et al. 2015; Thursby
& Juge 2017; Yang et al. 2009) .
The 16S rRNA gene is widely distributed amongst all prokaryotic
organisms and for that reason it is regularly used for identification of microorganisms
at taxonomic level. The data collected from 16S rRNA analysis supplies information
regarding the microbial composition found in a given ecosystem. However it does not
provide data in relation to the viability of the microorganisms present or their potential
functions (Eckburg et al. 2005; Hooper et al. 2012; Kurokawa et al. 2007; Qin et al.
2010). It should also be noted that the 16S based approaches are limited to bacterial
identification as viruses and parasites do not possess the 16S rRNA gene (Cénit et al.
2014). Similarly 18S rRNA is the eukaryotic nuclear homologue of the 16S rRNA gene
found in prokaryotic organism and can be used for identification of eukaryotes (Field
et al.1988).
In order to comprehend the gut environment, the gut biome and its
complexity extensive studies such as The European Metagenomics of the human
intestinal tract (MetaHIT) and the US Human Microbiome Project (HMP) were
undertaken. The objectives of the (MetaHIT) project are to establish the associations
between bacterial genes present in the human gut and human health and disease. The
study focused mostly on obesity and inflammatory bowel disease (IBD), both of which
are of increasing importance not only in Europe but globally. As part of the project a
reference catalog containing bacterial genomes recovered from the human intestine was
created. Over all 3.3 million non-redundant genes of microbial origin were identified
form 124 Europeans (Qin et al. 2010). Additionally bioinformatics tools such as
SmashCommunity were developed to act as stand-alone metagenomic annotation and
15

analysis pipelines, by provision of tools to approximate the quantitative functional and
phylogenetic composition of the metagenomes from the gut and to provide visual
representation of the analyses (Arumugam et al. 2010). Bioinformatics tools for
organization, storage and interpretation of the gathered information were also
developed. The frequencies of bacterial genes present in both healthy and sick
individuals were determined in order to gain insight into any possible correlations of
the bacterial genome carried by an individual to health and disease. Methods were
developed to study the functions of the bacterial genes, which are associated with
disease and the causal host-microbiome interactions. The findings of the project
highlighted the differences in the distribution of anti-inflammatory bacterial species in
the guts of healthy individuals versus the guts of sick individuals associated with IBD
(Dusko Ehrlich and MetaHIT consortium, 2010). The findings of the project should
allow for development of prognostic and diagnostic tools for gut microbiota modulation
for health optimization. More information about the project can be found at
http://www.metahit.eu.
The HMP project has created genomic sequence databases of over 2,200 strains
isolated from the human body. The samples have been obtained from a test group of
300 healthy adults aged 18 to 40. The samples were collected from five main body
locations including the gastro intestinal tract, urogenital tract, nasal cavity, skin and the
oral cavity. Over all 11,000 samples were collected. The findings of the project were
published in two main publications (Consortium, 2013) and (Human Microbiome
Project Consortium et al. 2012) general information about the HMP is available at
http://hmpdacc.org.

3.3 Functions of the gut microbiota
The gut microbiota confers gut colonization resistance to its host. The principle
of colonization resistance is that the indigenous gut microbiota makes it difficult for
foreign often invasive and pathogenic, bacteria to invade the gut, as it would have to
displace the already well-established commensal bacteria. Additionally the gut
microbiota protects the host from overgrowth of pathobionts, which can occur as a
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result of disturbance of the healthy gut microbiome (Buffie & Pamer 2013; Hooper et
al. 2012; Kamada Nobuhiko et al. 2013 ).
In an extensive review on

the role of

gut microbiota and chronic

gastrointestinal disease, Guinane & Cotter (2013) highlight the importance of what is
considered to be a “healthy gut microbiota” in the context of health and intestinal
disease. The review emphasizes the fact that while a healthy gut microbiota confers
benefits to the host its disruption may be a detrimental factor conferring development
of a number of intestinal disorders such as a range of bowel disorders, obesity, diabetes
and cancer (Fig 4). It is also proposed that manipulation of the human gut microbiome
by controversial methods such as faecal transplants can have a therapeutic effect in
treatment of aforementioned gastrointestinal disorders (Guinane & Cotter 2013).

Fig.4 The role of a healthy gut microbiota in health and intestinal disease. (This figure
was taken from Guinane & Cotter 2013).
The diversity of highly specific metabolites produced by the human gut
microbiota and the complexity of their effects on the host have been discussed by
Mousa et al. (2017), who has reviewed two decades of research in the area of the human
gut microbiota, its effect on health and disease of the host as well as the taxonomic
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diversity of the gut. The importance of the metabolic compounds such as amino acids,
lipids and glycolipids, post-transitionally modified peptides as well as non-ribosomal
peptides, oligosaccharides, polyketides and terpenoids and their functions in various
aspects of human health such as cytotoxicity, immunomodulation, antimicrobial
protection via production of antimicrobial peptides and production of antioxidants have
been highlighted (Mousa et al. 2017).
It is also understood that the complex often symbiotic relationships between
the human gut and the gut microbiome as well as organism present in different parts of
our bodies have shaped our evolution, immunity to disease and behaviors for thousands
of years suggesting that humans are super-organisms formed by those complex
interactions as discussed by Kramer & Bressan (2015).
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Fig. 5 Functions of the human gut microbiota (Figure adapted from O’Hara & Shanahan
2006).

4. Antimicrobials produced by gut bacteria
The production of antimicrobial agents is usually considered as a
manifestation of competition in bacteria found in the same or similar environmental
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niches (Cray et al. 2013; Mitri & Richard Foster 2013). Kommineni et al. (2015) has
investigated the role of conjugative plasmid pPD1 responsible for bacteriocin
expression in niche dominance by Enterococcus spp. in a mouse model colonized with
E. faecalis. The experiment revealed that the E. faecalis harboring the pPD1 plasmid
has replaced the native Enterococci present in the mouse gut, which did not have the
pPD1 plasmid. It was also reported that while in the intestine the pPD1 plasmid was
transferred to other E. faecalis strains. Overall the results have shown that the murine
gut was colonized with E. faecalis harboring the pPD1 plasmid while the other strains
of Enterococci including vancomycin-resistant Enterococci were eliminated,
effectively showing that bacteriocin expression can significantly influence the niche
competition within the gastrointestinal tract.
Antimicrobials are also often considered as signals used for communication
with other microorganisms (Abrudan et al. 2015). A study demonstrating that
microorganisms can use antibiotics as signals, which can be used to harmonize social
interaction with bacteria inhabiting the same niche was carried out by Abrudan et al.
(2015). Such behavior has been observed in antibiotic producing Streptomyces. The
study has shown that the production of antimicrobial agents has noticeably increased
due to competitive interactions between strains. Additionally it has been observed that
bacteria can have a number of responses to signals sent by competing strains such as
increase in the rate of production of antimicrobial agents, or suppression of
antimicrobial production by the competing strains, which effectively decreases the
direct threat posed by the competing strain (Abrudan et al. 2015)
It is also suggested that antimicrobial activity within dense microbial
populations can act as an effective approach in maintaining biodiversity of a niche. A
theoretical model developed by Czaran et al. (2002) looked at antibiotic production and
how it shapes the structure and diversity of microbial communities within a spatially
limited multispecies model. The model specified up to 14 different antimicrobials, it
also specified that each bacterial clone can have three types; Killer type - it can excrete
the antimicrobial while being resistant to it, resistant type – a bacterium which cannot
produce the antimicrobial but is resistant to it and a sensitive type - a cell with no
resistance or ability to produce the antimicrobial. The model takes into account the
metabolic cost of antimicrobial production/ resistance with the metabolic cost being the

19

lowest in the sensitive strains and the highest in the killer strains. The model also shows
that a niche dominance hierarchy; killer cells are dominant over the resistant cells, the
resistant cells are dominant over sensitive cells and sensitive cells can be dominant over
the killer cells due to the fact that their metabolic cost is the lowest. The model explains
that shifts in the dominance can be made through acquisition of novel toxin production
genes as well as the corresponding resistance genes by horizontal gen. At one extreme
it can be assumed that every strain in the model represents a different species in a
microbial community. This interpretation can be considered if novel antimicrobial
systems are present at low levels and the horizontal gene transfer is relatively rare in
that case species diversity is promoted. On the other side of the spectrum the model can
also be applied to an environment representative of different variants of the same
bacterial species. This scenario applies fast evolution of toxicity systems between
strains due to more likely horizontal gene transfers and gene recombination processes
resulting in polymorphic species. The intermediate and the most natural interpretation
of the model can be applied to a bacterial community made of different species, where
some may share common antimicrobial systems with low gene recombination rates
again promoting species diversity within a niche (Czaran et al. 2002).
Despite the fact that the human gut microbiota and its interactions with the
host are not fully understood and explored yet it is considered as a rich source of novel
metabolites and antimicrobials. In a review on the molecules produced by the human
gut microbiota, Donia and Fischbach (2015) discussed the fact that the spectrum of
microbial metabolites found in the human gut is as broad as that of any ecosystem,
however it was emphasized that a lot of those metabolites are produced specifically to
accommodate interactions with the host such as production of novel antimicrobials
conferring protection for the host (Donia and Fischbach, 2015). Bacteria found in the
human gut utilize various mechanisms, which allow them to outcompete and antagonize
other bacteria found in their ecological niche. There are a number of antimicrobials and
metabolites, which can be produced by the gut bacteria in order to directly inhibit or
limit growth of their competition. The activity of such antimicrobial agents can be very
specific and target one organism in particular or non-specific and target a broader range
of microorganism (Donia and Fischbach, 2015).

20

4.1. Non-peptide antimicrobials produced by gut bacteria.
Gut bacteria have been shown to produce non-peptide antimicrobials such
as organic acids, hydrogen peroxide (H 2O2), ammonia, diacetyl, phenolic compounds
and carbon dioxide (CO2) (Imlay 2008; Jay, 1982; Donia and Fischbach 2015).
Lactic acid and other organic acids such as propionic and acetic acids
produced by the lactic acid bacteria (LAB) found in the human gut lack specificity in
their spectrum of activity. Their mode of action is based on intrusion into the cytoplasm
membrane and subsequent suppression of the active transport system within the
targeted cell (Pessione, 2012). Another example of a non-specific, non-peptide
antimicrobial metabolite produced by the gut bacteria is H 2O2. Imlay (2008) discusses
the toxicity of superoxide and H2O2 to bacterial cells. The antimicrobial effect of H 2O2
is attributed to its ability to oxidize the cell as well as its molecular components. A
study by Pridmore et al. (2008) has shown that H2O2 producing L. johnsonii NCC 533
(La1) isolated from human intestine kills Salmonella enterica serovar Typhimurium
SL1344 in an in vitro model. Similar observations were reported by Hertzberger et al.
(2014). It should also be noted that H2O2 can be used by bacteria in combination with
lactic acid as previously reported for intestinal strains L. johnsonii NCC 533 and L.
johnsonii NCC 933 and vaginal isolate L. gasseri KS120 (Atassi & Servin 2010
Pridmore et al. 2008). The gut microbiota can also produce other antimicrobial
compounds such as diacetyl (Jay, 1982) ammonia, phenolic compounds and CO2 which
are also often associated with the antagonistic activity of the gut microbiome. However
due to the fact that their activity is not specific their applications in the food industry as
well as therapeutic uses are limited.

4.1.1 Short chain fatty acids (SCFA)
The human gut microbiota can confer pathogen resistance by producing
short chain fatty acids (SCFA). Production of SCFA involves the break down and
oxidation of non-digestible carbohydrates by the gut microbiota present in the
anaerobic lumen effectively releasing short chain fatty acids as byproducts of
fermentation. There are a number of biological pathways, which can result in formation
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of SCFA. Commonly the complex carbohydrates are broken down into simple sugars,
which are then fermented primarily by Bacteroidetes to form organic acids such as
SCFA and hydrogen. Clostridium spp. and other bacteria capable of butyrate
production are the second line of fermenters in the gut (Hooper et al. 2002; Sun and
O’Riordan, 2013). The three main SCFA produced in the intestine are acetate
propionate and butyrate, all of which carry out different functions in various organs.
Acetate is mostly used in the peripheral tissues of the human body such as cardiac
muscle and the skeletal tissues (Cummings and Macfarlane, 1997). Butyrate is
predominantly metabolized by the intestinal epithelium. It is then transformed to ketone
bodies and oxidized to carbon dioxide (Pennington 1952). It is estimated that butyrate
provides 60-70% of the energy needs to the colonic epithelium (Roediger, 1980). It has
also been shown that the metabolism of butyrate can prevent the oxidation of glucose
(Fleming et al. 1991). Propionate on the other hand is carried to the liver through the
portal vein. Studies on ruminants have shown that it plays a significant role as a
precursor of gluconeogenesis in the glucose uptake in ruminants (Bergman et al. 1966),
although its function in the human metabolism is not fully understood (Hooper et al.,
2002). While SCFA’s play very important role for the hosts energy homeostasis and
immune functions they also act as one of the main carbon sources for endogenous gut
microbiota (Fischbach and Sonnenburg, 2011) and when present at elevated
concentrations can become toxic to bacteria (Sun and O’Riordan, 2013).
A number of studies have shown that toxic effects of SCFAs were assigned
to non-ionized forms of the fatty acids in question, which is more likely to occur at low
pH such as that in the gastric tract. For example a study carried out by Baskett &
Hentges (1973) has shown inhibition of Shigella flexneri by acetic acid caused by
interference with the bacterium’s ability of intracellular accumulation of glutamic acid
and glucose, resulting in inhibition of glucose metabolism and subsequent inhibition of
the bacterium. The main process, which is understood to take place for SCFA
dependent toxicity relies on the entry of the fatty acids into the bacterial cytoplasm. The
non-ionized fatty acids are uncharged and small in size, thus are believed to be able to
easily diffuse across the bacterial membranes (Ricke, 2003). Once the fatty acids are
present inside the bacterial cytoplasm which normally has a pH of 6.5-7.5 the nonionized acids diffuse causing a buildup of SCFA anions and protons (Lambert and
Stratford, 1999). Subsequently the introduction of protons into the cytoplasm acidifies
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the intracellular compartments of the cell and degenerates the proton motive force as
described by (Axe and Bailey, 1995) for E. coli and its ability to transport acetate and
lactate across its cytoplasmic membrane. This in turn can have a detrimental effect on
the metabolic reactions and energy conservation of the cell which has been
demonstrated by (O’Byrne et al. 2002) where the growth E. coli K12 has been inhibited
by the reduction of its intracellular pH resulting from treatment with acetic acid. The
buildup of SCFA anions inside the cytoplasm can also cause serious implication to the
physiology of the cells including changes in the osmotic balance of the cell. SCFA
mediated damage to E. coli MG1655 cell membranes has been shown by (Royce et al.
2013). The toxicity induced by SCFA frequently results in inhibition of growth due to
pleiotropic defects taking place in the cellular processes. These defects are likely to
differ depending on the organism, metabolic pathways and environmental conditions
(Sun and O’Riordan, 2013). The effectiveness of SCFA growth suppression has been
demonstrated in vitro where the growth of E. coli strain O157:H7 was significantly
reduced (Shin et al. 2002). A study by Sun et al. (2012) has shown that elevated levels
of butyrate have the capability to impede virulence factor production in L.
monocytogenes thus implying that SCFA have a protective impact against infection
with L. monocytogenes. Additionally SCFA especially those present in the gut in high
quantities such as propionate and butyrate are responsible for down regulation of (SP1)
pathogenicity genes of S. typhimurium, which are necessary for successful invasion of
the human gut (Gantois et al. 2006; Lawhon et al. 2002). The toxic effects of SCFA
build up have been used by the food industry in order to control microbial populations
and improve food safety (Carpenter & Broadbent 2009; Ricke 2003). The addition of
SCFA to animal feed has been practiced with the aim to prevent or reduce the
colonization of vector animals such as chickens, which often shed pathogenic
organisms such as Salmonella subsequently contaminating the food product (Van
Immerseel et al. 2005).

4.2. Antimicrobial peptides produced by gut bacteria
Bacteria have the ability to produce antimicrobial peptides, those peptides
can be specific in their antimicrobial activity, meaning that that they can target specific
microorganism, which are often found in the same environmental niche as the peptide
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producing bacteria. Antimicrobial peptides can be categorized based on the location in
the bacterial cell where they were synthetized; i.e. they can be ribosomal or nonribosomal.
Non-ribosomal peptides are secondary metabolites produced by synthesis
of multi-functional peptides with enzymes. Examples of well-known non-ribosomal
antimicrobial peptides include polymyxin, penicillins and vancomycin, which are
currently used as antibiotics (Hancock and Chapple, 1999). Despite the fact that nonribosomal peptides belong to a quite large group of bacterial metabolites across a
number of various environments there is a relatively low number of non-ribosomal
peptides identified and characterized from the human gut (Donia and Fischbach, 2015).
Ribosomal antimicrobial peptides are typically made up of 10 to 50 amino
acids. Their antagonistic activity and specificity against bacteria is based on the
interactions between the peptide, the cell membranes and cell walls of bacterial cells
being attacked (Bahar & Ren 2013; Zhang & Gallo 2016). The levels of antimicrobial
peptide production in the gut as well as their bioavailability are dependent on the
producing strain as well as the environmental conditions. Identification and detection
of such compounds can be especially problematic when talking about the gut as the
physical environment and the limited bioavailability of such peptides can act as
obstacles. Modern developments in the field of bioinformatics can be used to recognize
and categorize genetic clusters found in samples from the human gut. Metagenomic
studies of the human gut microbiota such as those carried out by Cimermancic et al.
(2014), Donia et al. (2014), Drissi et al. (2015) and Walsh et al. (2015) all suggest that
the human gut is source of novel antimicrobial peptides.

4.2.1 Bacteriocins
Bacteriocins are an example of ribosomally synthesized antimicrobial
peptides. The first known bacteriocin “colicin” was discovered in 1925 as reported by
Cascales et al. (2007). Since the first discovery bacteriocins have been isolated and
characterized from a number of various environments including that of the human gut
(Czaran et al. 2002). Bacteriocin production is regarded as one of the key factors
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contributing to obtaining bacterial dominance at a niche level, which is often seen in
dense microbial populations such as that of the human intestine (Cotter et al. 2005;
Dobson et al. 2011; Guinane & Cotter 2013; O’Shea et al. 2009; Czaran et al. 2002;
Kommineni et al. 2015). It is anticipated that production of at least one bacteriocin is a
common trait in most bacteria (Dobson et al., 2011; Klaenhammer, 1988). While a high
number of bacteriocins has been identified from food sources a considerable amount of
bacteriocins have also been isolated from human gut microbes as can be seen in table
1. Additionally Drissi et al. (2015) suggests that there is a great number of potential
antimicrobial producers in the human intestine. A database of 317 bacterial genomes
holding 1,359 bacteriocin sequences was generated in the study, out of which 1050
were identified as bacteriocins from Gram-positive bacteria. Overall 962 of the
uncovered bacteriocins were synthesized by Firmicutes, one of the most common phyla
in the human gut (Arumugam et al. 2011).

Table 1. Examples of bacteriocins isolated from human gut bacteria and their
spectrums of activity.
Group

Bacteriocin

Class IId

Acidophilucin A

Class IIa

Avcin A

Producer ( gut
strain)
L. acidophilus
LAPT1060
E. avium 208/XA83

Class IIb

Bacteriocin B3AB3B

Enterococcus
faecalis B3A-B3B

Class IIb

Abp118

L. salivarius UCC
118

Class IId
Class IIa

ESL5
Bifidocin B

Class IIa
Class IIa

Enterocin A
Gassericin

E. faecalis SL-5
B.bifidum
NCFB1454
E. faecium DPC6482
L. gasseri LA39
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Antimicrobial
activity
Lactobacillus spp.

Reference

Listeria,
Enterococcus,
Lactobacillus,
Leuconostoc,
Pediococcus,
Carnobacterium
L. monocytogenes,
S. aureus,
methicillinresistant S.
aureus (MRSA)
C.perfringens
L. innocua,
B. coagulans
L. monocytogenes
EGDe
L.monocytogenes
LO28
P. acnes
L. plantrum,
L. monocytogenes
L. monocytogenes
L. acidophilus
JCM 5342,

Birri et al. 2010

Toba et al. 1991

Al-Seraih et al.
2017

Flynn et al. 2002
Corr et al. 2007

Kang et al. 2009
Yildirim et al.
1999
O Shea et al. 2009
Toba et al. 1991

Class IId
Class IId

Gassericin T
Gassericin KT7

L. gasseri SBT2055
L. gasseri KT7

Class IIb
Class Ia

Microcin M
Nisin O

E. coli Nissle 1917
B. obeum A2-162

Class Ia

Nisin Z

P. acidilactici MM33

Class II
Class II

Pediocin PA-1
Pediocin PA1AcH

P. acidilactici UVA1
L. lactis MM19

Class Ia

Rumionococcin
A

C. nexile, R. gnavus
E1

Class I

Thuricin CD

B. thuringiensis
DPC6431

L. plantarurn
JCM 1149, L.
gasseri LA 32,
LA 33, LA 38 and
LA 39
Not stated
B. cereus,
C. piscicola,
C. botulinum
C. perfringens,
E. faecalis,
L. acidophilus
L.delbrueckii,
L. helveticus,
L. plantarum,
L. sake,
L. lactis subsp.
lactis,
L. lactis subsp.
cremoris,
L. mesenteroides
L. ivanovii,
L. monocytogenes,
M. avus,
P.pentosaceus,
S. aureus
E.coli
C. perfingenes
Vancomycinresistant
Enterococci
(VRE)
L. monocytogenes
Vancomycinresistant
Enterococci
(VRE)
C. perfringens
C. difficile
C. difficile

Kawai et al. 2000
Zhu et al. 2000

Patzer et al. 2003
Hatziioanou et al.
2017
Millette et al. 2008

Mathys et al. 2007
Millette et al. 2008

Dabard et al. 2001
Rea et al. 2010

Bacteriocins can be sub-grouped based on their spectrum of inhibitory
activity. A narrow spectrum of activity is generally used a measure of targeting a
specific bacterium, often pathogenic, without affecting the natural bacterial population
of the niche. Bacteriocins can tackle some of the issues associated with conventional
antibiotics such as antibiotic resistance and are more often looked at as therapeutics for
applications in the veterinary and human industry (Chikindas et al. 2018; Dobson et al.
2012; Montalban-Lopez et al. 2011). A number of studies have shown antimicrobial
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properties of bacteriocins as an effective measure in controlling the populations of
gastrointestinal pathogens in vivo (Corr et al. 2007), such as Salmonella spp. (Casey et
al. 2004) and C. jejuni (Stern et al. 2006). A study by Corr et al. (2007) has shown the
protective effect of a bacteriocin delivered from a probiotic bacteria L. salivarius
UCC118 against infection with Listeria in mice. A study by Rea et al. (2011) has
shown that the sactibiotic group of bacteriocins such as thuricin CD can inhibit bacteria
such as C. difficile in a model of the distal colon while causing no adverse effects on
the desired members of the gut microbiota. On the other hand a broad-spectrum
bacteriocin can have a therapeutic potential targeting a number of microorganisms
(Langdon et al. 2016).
Additionally bacteriocins have a great potential to be used in the food
industry as preservatives due to their low levels of toxicity. Presently there are two
bacteriocins, which are commercially used in food preservation, those are pediocin PA1
(MicrogardTM, ALTA 2431, Quest) and nisin (Nisaplin, Danisco) (Simha et al. 2012).
Pucci et al. (1988) have demonstrated that pediocin PA-1 can inhibit the
growth of L. monocytogenes in half and half cream (commercially available
pasteurized), cottage cheese and in cheese sauce. 102-104 CFU/mL of L. monocytogenes
and 100AU/mL of pediocin PA-1were added to cream and the cheese sauce. 300g
cottage cheese portions were supplemented with 10AU/g and 50AU/g of pediocin PA1. All samples were kept at 4°C. Listeria counts for half and half cream and cheese
sauce were taken immediately after experimental set up after 1 day, 7 days and 14 days.
Listeria counts for cottage cheese were taken after 24 hr and 7 days. Rapid growth of
L. monocytogenes was observed in the negative controls (i.e. food product without
pediocin PA-1) of half and half cream and in cheese sauce while Listeria numbers
decreased in the cottage cheese. Supplementation of the food systems with pediocin
PA-1 has resulted in a rapid decrease in Listeria numbers in all tested foods.
Benech et al. (2002) has demonstrated an anti-Listeria effect of addition of
capsulated nisin Z in to cheddar cheese as well as its’ in situ production by Lactococcus
lactis subsp. lactis biovar diacetylactis UL719 used as the starter culture. The cheeses
were produced on a pilot scale with 105 – 106 CFU/mL of L. innocua added to the milk
used for cheese making, capsulated nisin Z at 300 IU/g was added to one cheese while
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nsin Z producing strain was added to the second cheese. Listeria number were reduced
by 3 log CFU/g in the cheddar with capsulated nisin Z and 1.5 log CFU/g in cheese
made with nisin Z producing starting culture immediately after cheese production was
complete. Following a 6 month ripening period the numbers of L. innocua in the cheese
made with encapsulated nisin Z were reduced to <10 CFU/g additionally nisin Z
maintained 90% of its initial activity. The cheese made with a nisin Z producing starter
culture had 104 CFU/g of Listeria and maintained 12 % of its initial activity.
Evidence also highlights the numerous novel applications of bacteriocins
in the food industry. It has been suggested that bacteriocins or bacteriocin producers
can be potentially integrated into food packaging, providing protection from spoilage
agents (Castellano & Vignolo 2006; Parada et al. 2007). This can be applied to already
existing food packaging solutions such as modified atmosphere packaging MAP and
can further extend their effectiveness in food protection (Liserre et al 2002). Liserre et
al (2002) has demonstrated the effectiveness of application of a bacteriocin producing
Lactobacillus sake to MAP. Bioactive food packaging infused with nisin has shown to
reduce the numbers of LAB present in sliced cheese and ham. Additionally the
packaging has shown to be effective in reduction of foodborne pathogens such as L.
inocua by ~2 logs in both cheese and ham and S. aureus by ~1.5 log in cheese and ~
2.8 logs in ham, similar results were obtained when vacuum packing the products. As
described by Scannell et al. (2000) lacticin 3147 was also immobilized and applied to
cellulose based food packaging and demonstrated activity for duration of 3 months
(Scannell et al. 2000). Furthermore L. curvatus CRL705 isolated from dry cured
sausage, producing bacteriocins lactocin 705 and lactocin AL705 has been reported to
reduce growth of B. thermosphacta and L. innocua in vacuum packed meat discs as
described by Castellano & Vignolo ( 2006). A study carried out by Chopra et al. (2015)
has demonstrated that sonorensin, a bacteriocin isolated from B. sonorensis isolate of
marine soil origin can effectively control the growth of L. monocytogenes and S. aureus
in food. Its application was demonstrated in a low density polyethylene (LDPE) film,
which was used as a coating on raw chicken meat spiked with L. monocytogenes or S.
aureus the samples were stored at 4°C, a controls of meat samples set up with untreated
films were also set up. All samples were observed for presence of unpleasant smell and
any visible signs of bacterial growth at set time intervals. The applications of the
sonorensin coated (LDPE) films were also investigated for applications in spoilage
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prevention during storage of fresh vegetables. An experiment was set up where fresh
tomatoes were packed in the active (LDPE) films and stored at 4°C, again controls were
set up with untreated (LDPE) films. The tomatoes were observed for visible signs of
spoilage and decay. The results of both experiments are presented in Fig.6.

Fig.6 Results of the study carried out by Chopra et al. (2015). Preservative effect of
coated low density polyethylene (LDPE) film during the storage of (A) meat (B)
tomatoes. (A) Meat samples were spiked with L. monocytogenes (1–3) and S. aureus
(4–6). Spoilage of meat is visible in meat samples packaged in control LDPE films (1
& 4) whereas no spoilage was observed in samples packaged with sonorensin (2 & 5)
and nisin (3 & 6) coated LDPE films. (B) Tomato samples (1) packaged in untreated
LDPE films showed signs of spoilage in contrast to no spoilage in case of tomatoes
packaged in sonorensin (2) and nisin (3) coated LDPE films. (This figure was taken
from Chopra et al. (2015).
Incorporation of bacteriocin producing bacteria into food products has also
been investigated by McAuliffe et al. (1999). Here a lacticin 3147 producing L. lactis
DPC4286 was used as a starter culture in the making process of cottage cheese. The
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aim of the study was to investigate the anti-Listeria properties of the bacteriocin when
produced in situ. The cheese was inoculated with 104 CFU/g of L. monocytogenes Scott
A and stored at 4°C, the results obtained in the assay demonstrated a 99% reduction in
the numbers of Listeria cells following a 5 day storage period. A control of non-lacticin
3147 cottage cheese was also inoculates with L. monocytogenes Scott A, however the
results showed no reduction in the number of Listeria cells.
Bacteriocins can also be potentially applied as anti-biofilm agents. A study
carried out Al-Seraih et al. (2017) has shown anti-biofilm properties of bacteriocins.
Here bacteriocin B3A-B3B produced by human gut isolate E. faecalis B3A-B3B has
demonstrated a significant reduction of L. monocytogenes biofilm formation on
stainless steel.

4.3 Identification of antimicrobials from the gut.
Identification of novel antimicrobials such as bacteriocins from the human
gut is often carried out with methods, which rely on detection of antagonistic activity
of the producing strain against the indicator strain. There are a number of variations
which can be applied to the assays while the principle remains the same (Hoover &
Harlander 1993). In deferred antagonism assays the selected potential antimicrobial
producing bacteria are grown on agar and subsequently overlaid with a layer of semisoft or sloppy agar seeded with an indicator strain. Here a positive result is indicated
with a zone of inhibition. A well diffusion assay implements the use of cell free
supernatant (CFS) of the producing strain and adding it to wells cut out in agar seeded
with an indicator strain. The CFS diffuses out into the agar surrounding the wells and
if antimicrobial peptide is present a visible zone of inhibition is produced (Hoover &
Harlander 1993). A study by O’Shea et al. (2009) is an example of a small-scale study
using culture-based approaches in order to isolate novel antimicrobials from the gut. In
total 278 gastrointestinal isolates were screened for activity agains L. innocua
DPC3572, L. bulgaricus , L.innocua DPC3572 and L. bulgaricus LMG 6901 in a well
diffusion assay. Subsequent characterization of the isolates revealed 23 individual
strains producing bacteriocin like antimicrobials and three class II bacteriocins
identified as enterocin A, salivaricin A and salivaricin P.
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Recent developments in molecular tools allow for identification of clusters
of putative bacteriocins in genomes from environmental samples. Public software and
databases which are most commonly used for research such as BAGEL and
BACTIBASE provide large numbers of genetic sequences (Hammami et al. 2010; van
Heel et al. 2013). Walsh et al. (2015) used an in silico approaches in their screening
methodologies in order to mine for potential bacteriocin cluster in bacterial genomic
sequences. BAGEL3 (i.e. a bacteriocin-mining tool) was used to identify possible
bacteriocins. Consequently the resultant genome clusters were manually annotated and
an evaluation of potential bacteriocin genes was carried out. As a result 74 bacteriocin
clusters were identified form 130 putative producers.
While metagenomic in silico methods allow for identification of
antimicrobials produced by previously uncultured residents of the gut microbiota, their
subsequent characterization and evaluation of possible application may not always be
possible (Hiergeist et al. 2015).

Fig.6 Bioassays used for identification of antimicrobials produced by the gut isolates
(A) a deferred antagonism assay (B) well diffusion assay (This figure was obtained
from Dr. Máire Begley).
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5. Evidence that gut microbiota inhibits Listeria.
Studies dating back to the 1970s suggest that the gut microbiome has the
ability to protect the host from becoming infected with L. monocytogenes. Zachar &
Savage (1979) carried out experiments with germ free mice (GF) and specific pathogen
free (SPF) mice. Both groups were inoculated with L. monocytogenes. Following a 24
hr incubation period the bacterium colonized colon and the cecum tissue of the GF
mice. In contrast the SPF remained healthy, suggesting that the presence of the gut
microbiota in the SPF mice had a protective effect and successfully inhibited L.
monocytogenes colonization.
Corr et al. (2007) has demonstrated that a human isolate L. salivarius
UCC118 has the ability to produce bacteriocin Abp118 which can sucessfully inhibit
infection with L. monocytogenes EGDe and L. monocytogenes LO28 in a mouse model
by 99%. The in vivo trials were carried out as follows; mice were were fed with the
probiotic strain L. salivarius UCC118 at a concentration of 1 x109 CFU per mice for a
duration of 3 or 6 days prior to administration of 2 x 10 9 CFU of L.monocytogenes
EGDe per mouse. A placebo test group was fed with phosphate buffered saline (PBS)
for 3 days prior to infection with the pathogen. In order to demonstrate that Listeria
was in fact inhibited by bacteriocin Abp118 two controls were set up in the experiment.
In one mice model was infected with a mutant stain of L. salivarius UCC118 unable to
produce the bacteriocin, a second control was set up with L. monocytogenes engineered
to express immunity protein AbpIM associated with imunity to to Abp118. The results
have demonstrated that the mice treated with a mutant strain of L. salivarius UCC118
prior to infection with L. monocytogenes became infected with the pathogen.
Furthermore no effect of antimicrobial treatment was observed mice infected with L.
monocytogenes expressing immunity to the antimicrobial suggesting that the antiListeria activity was in fact mediated by bacteriocin Abp 118. Additionally typical
infection associated with L. monocytogenes was observed in the placebo group fed with
PBS.
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Fig. 7 Results of the study carried out by Corr et al. (2007) (A) Feeding mice with L.
salivarius UCC118 can reduce the infectivity of L.monocytogenes by 99% in an animal
model. (B,C) the antinfective activity was linked to bacteriocin produced by L.
salivarius UCC118. (This figure was obtained from Prof. Colin Hill and was originlly
adapted form Corr et al. 2007).
A study performed by Becattini et al. (2017) has demonstrated that the gut
microbiota of mice can noticeably reduce the colonization of the gut lumen with
pathogenic L. monocytogenes 10403S. The study has demonstrated that antibiotic
treatment prior to infection with the intestinal pathogen effectively increases the growth
of the pathogenic bacterium in the intestine and the susceptibility to disease. In the
experiment mice treated with streptomycin (STREPTO) 24 hr prior to being infected
with 102 CFU of L. monocytogenes. High levels of Listeria colonization were observed
in the intestines of those animals, additionally the test animals displayed other
symptoms of including faecal shedding of the pathogen exceeding a 10 day period,
weight loss, diarrhea and general symptoms of distress. It was observed that the
pathogen had penetrated the intestinal epithelium and spread into the mesenteric lymph
nodes and subsequently to the spleens and livers of the antibiotic treated animals, this
however was not observed in a control group of animals fed with PBS suggesting that
a healthy gut microbiota i.e. not treated with antibiotics can provide colonization
33

resistance against L. monocytogenes. Similar results were observed in mice who were
given a single dose of clindamycin (MNVC) and were infected with a sub-lethal dose
of L. monocytogenes 24 hr following the antibiotic treatment. It was observed that
clindamycin treatment resulted in an increased numbers of Listeria cells in the intestinal
lumen and tissue.

Fig. 8 Antibiotic treatment predisposes to severe L. monocytogenes infection. Mice were
treated with a single i.p. injection of clindamycin or PBS and then orally infected with L.
monocytogenes. The bar charts show the number of L. monocytogenes (Lm) in the small
intestine (SI) and large intestine (LI) walls and contents after 24hrs. The pictures show stains
of colonic tissue 3 days after infection. In this experiment mice were treated with
streptomycin (STREPTO) or clindamycin (MNVC). (This figure was taken from Becattini et
al. 2017).
Similar findings were observed by Czuprynski & Balish (1981) who also
demonstrated that the gut microbiota of healthy rats had a protective effect against L.
monocytogenes as the bacterium did not colonize the guts of rats with indigenous gut
microbiota. The study has also revealed that antibiotic treatment increases the susceptibility
to L. monocytogenes infection and that gut microbiota delivers defense against L.
monocytogenes infections in immune-compromised hosts.
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6. Conclusions and future directions
L. monocytogenes is a foodborne pathogen, which is commonly found in the
environment. It has an outstanding ability to persist in various environments and withstand
exposure to harsh conditions of food processing and other environmental stresses such as
extreme temperatures, pH and water activity. Furthermore Listeria has the ability to persist
in the food processing environments due to it’s ability to form biofilms in so-called
harbourage sites which are difficult to clean. When growing in a biofilm form Listeria shows
increased levels of resistance to antimicrobial agents. Such persistence in the food industry
can potentially lead to post processing contamination of food product, which is particularly
dangerous especially in ready to eat foods as Listeria causes a rare but highly infective
foodborne disease listeriosis.
The fact that Listeria persists in the environment makes its elimination from the food
chain very difficult. Efforts are therefore focusing on controlling the pathogen in the food
processing environment and in food products. Methods of control under investigation include
different sanitizers, photodynamic inactivation, bacteriophage and bacteriocins (NicAogáin
& O’Byrne 2016).
Novel antimicrobial compounds produced by the members of the human microbiome
could be purified and potentially applied as a measure for decreasing and controlling Listeria
populations in the food industry. Potential applications of such antimicrobials include
reducing biofilm formation on stainless steel and other surfaces. Additionally gut derived
antimicrobials can be potentially used as a natural preservatives or food ingredients and can
be incorporated into food packaging with the aim of extending the shelf life and safety of the
products associated with outbreaks of Listeria.
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Chapter 1

Isolation and identification of human gut-derived bacteria
with anti – Listeria monocytogenes activity
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INTRODUCTION
In recent years the human microbiota has been researched in great detail.
Evidence found in numerous studies shows that the human gut microbiota has an impact
on many aspects of human health including immune function, nutrition, physiology and
metabolism (Cénit et al. 2014; Eckburg et al. 2005; Guinane & Cotter 2013). A growing
number of studies support the theory that the gut microbiota plays an important role in
the predisposition and susceptibility to diseases by carrying out protective functions
(Cénit et al. 2014). It has been proposed that antimicrobials produced by commensal
human bacteria play a fundamental role in establishing a long term symbiotic
relationship with the host (Zheng et al. 2015).
Experiments with animal models have provided evidence to suggest that
intestinal microbes provide defense against L. monocytogenes infection. Zachar &
Savage (1979) performed experiments with two groups of mice; one gnotobiotic and
one specific pathogen free (SPF) where the indigenous microbiota was present. Both
groups were orally inoculated with ~ 100 CFU/mL of L. monocytogenes. After 24hr L.
monocytogenes colonized the gnotobiotic mice and reached 105 to 107 bacterial cells
per gram of stomach tissue and 108 to 109 bacterial cells per gram of cecum and colon
tissue. On the other hand, the SPF mice stayed healthy after oral inoculation with up to
5 x 107 bacterial cells with L. monocytogenes isolated from the gastrointestinal tract of
only one of a total of 27 SPF mice. The study showed that establishment of L.
monocytogenes was prevented by the presence of the indigenous gut microbiota in the
SPF mice. Similar findings were observed by Czuprynski & Balish (1981) who
demonstrated that L. monocytogenes colonization of germ-free rats reached 1010 to 1011
bacterial cells per gram of dry weight within 24 hr following oral inoculation. Here the
indigenous microbial flora present in healthy rats also demonstrated a protective effect
against L. monocytogenes as the bacterium did not colonize the guts of rats with
indigenous gut microbiota. It has also been shown that treatment with antibiotics
increases the predisposition to becoming infected with L. monocytogenes and that the
gut microbiota delivers defense against L. monocytogenes infections in immunecompromised hosts (Becattini et al. 2017). As already mentioned in the literature
review, it is suggested that the gut microbiome is a source of large numbers of
bacteriocin-producing bacteria (Drissi et al. 2015).
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The antimicrobial properties of bacteriocins have shown to be an effective
measure in controlling the populations of GI pathogens in vivo (Corr et al. 2007;
Guinane & Cotter 2013). Studies have shown that L. monocytogenes (Corr et al. 2007),
Clostridium difficile (Rea et al. 2011), Salmonella spp. (Casey et al. 2004) and
Campylobacter jejuni (Stern et al. 2006) can all be controlled with the use of
bacteriocins. Antimicrobial production has been demonstrated by bacterial species
isolated from the human gut (Al-Seraih et al. 2017; Birri et al. 2010; Birri et al. 2013;
Booth et al. 1977; İspirli et al. 2015; O’Shea et al. 2009) and many more. This provides
a strong basis on which a hypothesis can be made that screening of the gut microbiota
has the potential for successful isolation and identification of novel antimicrobials such
as bacteriocins (O’Shea et al. 2009). The aim of the current study is to isolate antiListeria bacteria of human-gut origin, identify them and characterize the antimicrobials
produced by the selected gut-derived isolates.
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MATERIALS AND METHODS
Bacterial strains and culture conditions. All bacterial strains used in
this study and the growth conditions used for their cultivation are listed in Table1.
Table 1. Growth conditions used for cultivation of bacterial strains used in the study.
Bacterial cultures were grown in brain heart infusion (BHI) broth/ agar (Oxoid), or M17
agar/broth (Lab M) supplemented with 1% (w/v) glucose (Oxoid) i.e. GM17.
Strain

Listeria monocytogenes

Growth

Incubation

media

temperature

BHI

37 C

Source

Comment/ Reference

UCC culture collection

Serotype 1/2a, isolated

10403S
Listeria monocytogenes EGDe

from human skin lesion
BHI

37 C

UCC culture collection

Serotype 1/2a, isolated
from rabbit tissue

Listeria monocytogenes F2365

BHI

37 C

UCC culture collection

Serotype 4b, a cheese
isolate from 1985
Californian listeriosis
outbreak

Listeria monocytogenes LO28

BHI

37 C

UCC culture collection

Serotype 1/2 c, isolate
from faeces of a healthy
pregnant woman

Lactococcus lactis NZ9700

GM17

30 C

CIT culture collection

Nisin producer

Lactococcus lactis HP

GM17

30 C

CIT culture collection

Indicator strain sensitive
to nisin

Listeria innocua 13568t

BHI

37 C

Teagasc Moorepark
culture collection

Enterococcus faecium

BHI

37 C

DPC1146

Teagasc Moorepark

Enterocin A producer

culture collection
(O’Keeffe et al., 1999)

Enterococcus faecium

BHI

37 C

DPC6482
Enterococcus faecium EM342-

BHI

37 C

BC-1

Teagasc Moorepark

Enterocin A producer

culture collection

(O’Shea et al., 2009)

Teagasc Moorepark

Enterocin B producer

culture collection

Micrococcus luteus

BHI

37 C

UCC culture collection

Staphylococcus aureus

BHI

37 C

CIT culture collection

ATTC6538
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Salmonella enteritidis

BHI

37 C

CIT culture collection

Pseudomonas aeruginosa
DSM1128

BHI

37 C

CIT culture collection

Bacillus subtilis

BHI

37 C

CIT culture collection

CIT- Cork Institute of Technology, UCC- University College Cork

Assembly of human faecal bacterial banks. The faecal samples were
acquired from a previous study in our lab and were originally obtained from 23 lean
male donors with a body mass index of <25 (Clarke et al., 2014). The samples were
stored at -80 C until ready to use. The faecal samples were thawed on ice and 1 g
portions of each were aseptically transferred into sterile plastic bags and sealed. All
subsequent manipulations were performed in an anaerobic chamber (Don Whitley). 9
mL of Maximum Recovery Diluent (MRD) (Merck) was added to each 1 g sample of
faeces and samples were manually agitated until all soluble constituents were dissolved.
The resulting faecal water was serially diluted in MRD and 100μL of each dilution was
spread plated in triplicate onto Wilkins-Chalgren Anaerobe (WCA) agar (Oxoid).
Plates were incubated anaerobically at 37 C for 48 hr. All colonies obtained for an
individual faecal sample were then pooled and transferred to a sterile stock bottle (i.e.
1.5 mL WCA broth was pipetted onto the surface of a plate, colonies were scraped into
the broth using a sterile plastic spreader. The resultant broth containing bacteria was
removed by pipetting and transferred onto the surface of another plate of colonies from
the same faecal sample. This was continued until all colonies for that faecal sample
were recovered). 500 L of sterile 80% (v/v) glycerol ( final concemtration 40%) was
added to the stock tubes and these faecal bacterial banks were stored at -80 C.
Selection of a Listeria monocytogenes indicator strain. A deferred
antagonism assay was carried out in order to determine the sensitivity of the indicator
strains L. monocytogenes EGDe, L. monocytogenes F2365, L. monocytogenes L028 and
L. monocytogenes 10403S to nisin. The nisin producing strain Lactococcus lactis NZ
9700 was grown overnight in GM17 broth at 30 C for 18 hr. After the incubation time
was competed 20 L of the overnight was spotted onto the centre of a GM17 plate in
triplicate, the plates were then left to dry in a biosafety cabinet and incubated overnight
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at 30 C. Simultaneously, individual colonies of the indicator strains were inoculated
into 10 mL of fresh BHI broth and incubated at 37 C for 18 hr. After the incubation
time was completed the spotted GM17 plates were examined for contamination and
exposed to a 30 min UV light treatment in a CL-1000 Ultraviolet Crosslinker (UPV) in
order to kill off the bacteriocin producing cells. The plates were then overlaid with 10
mL of BHI sloppy 0.7% (w/v) agar seeded with 100 L of indicator overnight cultures
and incubated at 37 C for 18 hr. After the incubation was competed the zones of
inhibition were measured (including the bacterial spot).
Identification of gut-derived bacteria that directly antagonize L.
monocytogenes. When required, faecal bacterial banks were removed from the -80 C
freezers and thawed on ice. 100μL of the bank was serially diluted in MRD and aliquots
were plated onto WCA agar and incubated anaerobically at 37 C for 48 hr. Individual
colonies were manually transferred into WCA broth in 96 well plates i.e. each colony
was picked with a sterile pipette tip and transferred to an individual well of a 96 well
plate containing WCA broth. The 96 well plates were incubated at 37 C for 24 hr after
which wells were checked for turbidity and 2μL aliquots were transferred onto WCA
agar plates using a multichannel pipette. The plates were incubated anaerobically at
37 C for 24 hr. All dilutions, plating, incubations etc. were performed in an anaerobic
chamber. Plates were checked for growth, removed from the anaerobic chamber and
exposed to UV light in a CL-1000 Ultraviolet Crosslinker for 45 min in order to kill all
viable cells. The plates were subsequently overlaid with sloppy BHI agar 0.7% (w/v)
seeded with 1% L. monocytogenes 10403S overnight culture. The plates were incubated
aerobically at 37 C for 24 hr after which they were examined for zones of inhibition.
Selection of gut-derived strains for further investigation and stocking.
59 gut-strains, which inhibited Listeria i.e. produced zones of inhibition in the
screening assay, were selected for further investigation. These strains were chosen on
the basis of their colony morphologies and zone sizes i.e. it was hoped that by selecting
strains with different appearance and zone sizes that different type of bacteria would be
identified. The 59 strains were obtained from the 96 well master stock plates. The plates
were removed from the -80 C freezer and left to thaw out in a biosafety cabinet for 15
min. The plates were then transferred into an anaerobic hood and once fully thawed out
the contents of each well of interest were mixed with a sterile pipette tip. 20 L aliquots
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of each were transferred into 10 mL WCA broth. Inoculated broth was then mixed with
a vortex and incubated anaerobically at 37 C for 24 hr. Overnight cultures were
vortexed and streaked onto WCA agar plates. Plates were incubated anaerobically at
37 C. Cell morphology was recorded after 24 hr and after 72 hr incubation. Any sample
containing more than one colony type was re-streaked on fresh WCA agar. Stocks were
prepared by adding 500 L aliquots of fresh overnight cultures to 500 L of 80% (v/v)
glycerol in sterile stock tubes. These stocks are stored at -80 C for long-term storage.
Confirmation of the anti-Listeria activity of the gut-derived strains.
Shortlisted gut- derived isolates were grown overnight at 37 C in 10 mL of WCA broth.
5μL aliquots of overnight cultures were then spotted onto the center of fresh WCA agar
plates and incubated anaerobically at 37 C for 24 hr. Following the incubation the
WCA agar plates were checked for growth and were exposed to UV light in a CL-1000
Ultraviolet Crosslinker for 45 min in order to kill any viable cells. The plates were then
overlaid with 5 mL BHI sloppy 0.7% (w/v) agar that was seeded with 1% L.
monocytogenes 10403S overnight culture. The plates were incubated at 37 C for 24 hr
after which they were checked for the presence of zones of inhibition. Zones were
measured with a Vernier calipers.
Gram staining. All gut – derived isolates were streaked onto fresh WCA
agar plates and incubated anaerobically at 37 C for 24 hr. Individual colonies were then
picked and a standard Gram stain procedure was carried using a Staining Kit (Sigma
Aldrich) in accordance to the manufacturers’ instructions.
MALDI-TOF MS. All gut-derived isolates were anaerobically inoculated
from WCA broth onto fresh WCA agar and incubated anaerobically at 37 C for 24 hr.
Individual colonies of each isolate were deposited onto the surface of a MALDI target
plate in duplicate (one thick and one thin coat of sample for increased chance of
identification). Each well of the target plate was coated with 1μL of matrix solution and
left to dry at room temperature for 5 min. The target plate was then inserted into the
Burker Daltonik MALDI Biotyper located at Cork University Hospital (CUH). The
data collected was classified in accordance to Burker Taxonomy database of CUH. The
database allowed for identification of microorganisms by ranking the mass of cell
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proteins into peaks, then the peaks were ranked based on the score of the peak against
the database. A score of 2.3-3.0 indicated a highly probable species identification, 2.992.00 indicated a secure identification and a probable species identification, 1.99-1.70
indicated a probable genus identification and a score lower than 1.69 indicated no
reliable identification.
16S rRNA partial gene sequencing. Individual colonies from WCA agar
plates were grown anaerobically in 10 mL WCA broth 37 C for 24 hr. Genomic DNA
was extracted from 1.5 mL of overnight culture using the BlueElute Bacterial
GenomicKit (Sigma Aldrich) in accordance with the instructions given by the
manufacturer. Extracted genomic DNA was quantified using a NanoDrop (Thermo
Scientific). Genomic DNA was used as a template in PCRs with universal 16S rRNA
primers

(CO1

5’

AGTTTGATCCTGGCTCAG3’

and

CO2

5’TACCTTGTTACGACTT3’). The Platinum PCR super mix (Invitrogen) was used
according to manufacturers’ instructions. PCR products were purified using the
QIAquick PCR Purification kit (Qiagen) and subsequently quantified with the Qubit
dsDNA HS Assay kit (Molecular Probes Life Technologies) again in accordance to
instructions provided by the manufacturer. Purified PCR products were sequenced by
GATC Biotech using the 16S primers CO1 and CO2. Homology searches were
performed using the BLAST algorithm (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
Investigation of the anti-Listeria activity of cell free supernatants and
whole cell extracts. Individual colonies of gut-derived isolates from taken from WCA
agar were inoculated into fresh WCA broth and incubated anaerobically for 24 hr at
37 C. 2 mL aliquots of each overnight culture were centrifuged at 12,000 rpm for 6
min. 1 mL aliquots of the cell free supernatant (CFS) were removed from the cell pellet
and transferred into a fresh sterile eppendorf tubes and were re- centrifuged at 12,000
rpm for 6 min. 500μL aliquots of the CFS were then transferred into fresh sterile
Eppendorf tubes. The approximate pH of CFS was measured with pH strips (Macherery
– Nagel). Cell pellets were used to obtain whole cell extracts (WCE) as described by
Field et al. (2012). For the WCE preparation the cell pellets were re-suspended in 2.5
mL of 70% IPA 0.1% TFA (isopropanol + trifluoroacetic acid) and placed on a shaking
incubator (9,000 rpm) for 3 hr at room temperature. Tubes were then centrifuged (6,500
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rpm x 10 min) and 1 mL was removed and transferred to fresh sterile Eppendorf tubes.
BHI agar was seeded with L. monocytogenes 10403S i.e. aliquots of a L.
monocytogenes 10403S overnight culture (0.5% inoculum) were added to freshly
autoclaved BHI agar that was cooled to ~50 C and poured into sterile Petri dishes. The
plates were allowed to set for 20 min inside a biosafety cabinet after which wells were
bored in the agar with a sterile P200 pipette tip. 45μL of the CFS and WCE extracts
were added to individual wells. The CFS and WCE from the nisin producer L. lactis
NZ9700 were added to the wells as positive controls. The plates were incubated for 24
hr at 37 C after which they were examined for zones of inhibition.
Deferred antagonism assays to examine the spectrum of activity of gutderived strains. The ability of the 59 gut-derived strains to inhibit a selection of
indicator strains, namely L. monocytogenes 10403S, L. monocytogenes F2365, L.
monocytogenes LO28, L. monocytogenes EGDe, L. innocua, E. faecium, E. hirae, S.
aureus, S. enteritidis, B. subtilis, E. coli, M. luteus, L. lactis HP and P. aeruginosa,
were examined by performing agar-based deferred antagonism assays. L. lactis HP was
streaked onto GM17 agar and incubated at 30°C for 18 hr. All other strains (the 59 gutderived isolates and the indicator stains) were taken out of -80°C stock onto fresh BHI
agar and incubated at 37°C for 18 hr. The 59 gut-derived strains were then grown in
BHI broth and incubated at 37°C for 18 hr. 50µL aliquots were spotted onto the center
of fresh BHI agar plates and plates were incubated 37°C for 18 hr. The spot plates were
UV treated for 30 min in a CL-1000 Ultraviolet Crosslinker, the plates were then
overlaid with 5 mL of sloppy 0.7% (w/v) BHI/ GM17 agar seeded with 1% inoculum
of an overnight of the relevant indicator strain (grown in BHI/GM17 at 37°C/ 30°C as
appropriate). The overlaid plates were incubated at 37°C for 18 hr and examined for
zones of inhibition.
Cross immunity deferred antagonism assays. Selected gut-derived
isolates and an enterocin A producer E. faecium DPC 6482 and an enterocin B producer
E. faecium EM342-BC-1 were taken out of stock onto fresh BHI agar and incubated at
37°C for 18 hr. Fresh colonies were transferred into 10 mL of fresh BHI broth and were
incubated at 37°C overnight. 10 L aliquots of the bacterial cultures were then spotted
onto BHI agar and incubated at 37°C for 18 hr. The plates were subsequently UV
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treated for 30 min in a CL-1000 Ultraviolet Crosslinker and overlaid with 5 mL of
sloppy BHI 0.7% (w/v) agar seeded with 1% inoculum of other gut-derived strains
originating from the same faecal bank / or the enterocin A/ B producing strains. The
plates were then incubated at 37°C for 18 hr after which they were examined for zones
of inhibition.
Deferred antagonism assays in the presence of proteinase K. Deferred
antagonism assays were carried out using the previously described method except with
the addition of proteinase K (Sigma- Aldrich). All short-listed gut-derived strains were
spotted onto two separate plates, grown overnight and subsequently UV treated for 30
min in a CL-1000 Ultraviolet Crosslinker. One plate was then left untreated as a control.
On the other plate 2µL of a proteinase K stock (50 mg/mL) was spotted next to the
bacterial spot. All plates were incubated at 37°C for 1hr. Plates were then overlaid with
0.7% (w/v) sloppy BHI agar seeded with 1% L. monocytogenes 10403S or E. faecium
DPC 6482 overnight cultures and were incubated at 37°C for 18 hr after which they
were examined for zones of inhibition.
PCRs with primers for enterocin genes. Selected gut-derived strains and
enterocin A and enterocin B producers were grown overnight in BHI broth at 37 C for
18 hr. DNA was extracted from 1.5 mL of overnight cultures with the BlueElute
Bacterial Genomic Kit (Sigma Aldrich) in accordance with the instructions given by
the manufacturer. The sequences of the genes responsible for the production of
enterocin A (primers TH 10 and TH11) were obtained from Aymerich et al., (1996)
and O’Shea et al., (2009) and were synthesized by Eurofins Genomics. The gene
sequences responsible for production of enterocin B, enterocin L50A, enterocin L50B,
enterocin P, duracin A, duracin B, duracin Q and hiracin JM79 were obtained from the
NCBI nucleotide search engine and GenBank (https://www.ncbi.nlm.nih.gov/
nuccore/). Oligonucleotide primers were designed for these genes with Snap Gene,
(sequences are provided in Table 2) and were synthesized by Eurofins Genomics. The
PCR conditions used for detection of the enterocin A gene were as follows: initial
denaturation step at 95°C for 5 min followed by 30 cycles of denaturation at 95°C x 1
min, annealing at 47°C x 1 min and extension at 72°C x 1 min, followed by a final
extension step at 72°Cx 1 min. The PCR products were run on a 2.5% agarose gel
containing SYBR Safe (Invitrogen) at 100V for 1hr and visualized under UV light
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miniBIS pro (DNR Bio-Imagining Systems). The approximate size of products was
determined by comparison to the molecular weight marker HyperLadder IV (Bioline).
The same conditions were used for detection of enterocin B, enterocin P duracin A,
duracin B, duracin Q and hiracin JM79 except the annealing temperature was set to
50°C, similarly a change to the annealing temperature was made in attempts to amplify
enterocin L50A and enterocin L50B genes (annealing temperature set to 49°C).
Table 2. Sequence of primers used to detect known bacteriocin genes
Primer name

Primer sequence

Bacteriocin

Sequence

encoded by the

accession

structural gene

number

Reference

targeted
TH10

5’GAT T ATG AAAC AT TT AAAAAT TT TG TC

Enterocin A

-

3’

(O' Shea et
al., 2009)
(Aymerich et
al., 1996)

TH11

5’ CAA G AA T AT C AG AAT ATT T AG

Enterocin A

-

G3’

(O' Shea et
al., 2009)
(Aymerich et
al., 1996)

EntcinB_Fr.

5’ GTT ATTC CT C AT TC AG AGT TCC 3’

Enterocin B

U87997.1

This study

EntcinB_ Rv.

5’ GAAG AG AAAAAAC TCG T AATG AG3’

Enterocin B

U87997.1

This study

E ntci nL50 A_Fr .

5’ GCTT CT TT TGG AC TC AT AACC 3’

EnterocinL50A

AJ223633.1

This study

E ntci nL50 A_ R v.

5’ GCGTT AAGCCG AATG TT T AC 3’

EnterocinL50A

AJ223633.1

This study

E ntci nL50B_Fr .

5’ GGCTTG AT AT AG TTG C AT TT C AT C 3’

EnterocinL50B

AJ223633.1

This study

E ntci nL50B_ R v.

5’ CT AT C AT T AAC T AAATT TTG GGGTG G

EnterocinL50B

AJ223633.1

This study

3’
E ntci nP_ Fr .

5’ GAC AC ACG ATT T TCT AGGG AATG 3’

Enterocin P

AF005726.1

This study

E ntci nP _R v.

5’ AGT TC CC AT ACC TCG C AAAC 3’

Enterocin P

AF005726.1

This study

DurA_Fr

5’ CAC GGGT AT AG C AAGC TC3’

Duracin A

HQ696461.1

This study

DurA_Rv

5’ CATCC CC T AT ATT T TTGG CT CT 3’

Duracin A

HQ696461.1

This study

5’

Duracin B

HQ696461.1

This study

DurB_Fr.

GTTGG GT AG AT TGG AAT AAAGC TT C3’
DurB_Rv.

5’ GCTGGGC T AT AAAAC ACC ATTG 3’

Duracin B

HQ696461.1

This study

DurQ_ Fr.

5’ CCATG AT AC AG TC ATG TTG T AAT AC3’

Duracin Q

AB298307.1

This study

DurQ_Rv.

5’

Duracin Q

AB298307.1

This study

CTT CC AG AT AC TC TT AG ATG AT AAG C3’
Hir J M79_Fr .

5’ GGCGTT ACT TGG T AG T AT CG3’

Hiracin JM79

DQ664500.1

This study

Hir J M79_Rv.

5’ CAC CT TCGG TG AAAT TGT TG3’

Hiracin JM79

DQ664500.1

This study
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RESULTS
Assembly and preparation of human bacterial banks. A total of 23
bacterial banks from 22 human faecal samples have been created and stored at -80 C
(two separate samples of faeces number 26 were collected). The number and
morphology / appearance of the colonies were noted. It was recorded that on average
107 CFU/ mL of cells were recovered from each faecal bank (data not shown). A variety
of colony morphologies were also observed; small white pinpoint colonies, beige
irregular colonies, large irregular semi-transparent colonies etc.
Selection of a L. monocytogenes indicator strain. L. monocytogenes
10403S demonstrated the highest sensitivity to nisin, with an average zone of inhibition
of 23 mm, when compared to the average zones of inhibition produced by L.
monocytogenes EGDe of 19mm (Fig.1), L. monocytogenes F2365 has a zone of
inhibition of 16 mm and L. monocytogenes L028 has an average zone of inhibition of
17.3 mm. It was therefore decided to use L. monocytogenes 10403S as the indicator for
the screening assays with the bacterial faecal banks.

A

B

C

D

Fig.1 Lactococcus lactis NZ9700 (a nisin producer) was grown overnight in GM17
broth and incubated at 30° C. Following the incubation 10 L aliquots of the overnight
culture were spotted in the center of fresh GM17 agar plates and incubated overnight
at 30° C. The plates were then UV treated for 30 minutes in order to kill any viable
cells. The UV treated plates were subsequently overlaid with fresh BHI sloppy agar
seeded with 1% inoculum of (A) L. monocytogenes 10403S (B) L. monocytogenes
EGDe (C) L. monocytogenes L028 (D) L. monocytogenes F2356. The plates were
subsequently incubated at 37° C overnight and examined for zones of inhibition.
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Identification of gut-derived bacteria strains that directly antagonize
L. monocytogenes. The ability of gut-derived bacteria to inhibit L. monocytogenes
10403S was investigated using agar-based deferred antagonism assays as described in
Materials and Methods. Differences were observed between the different faecal banks.
For example, for 3 faecal banks only one distinct zone of inhibition was observed for
one of the samples whereas 127 colonies from another faecal sample produced distinct
zones of inhibition (Fig.2). It was noted that several of the producing colonies looked
similar so it is likely that particular gut strains are represented multiple times on the
plates. A total of 4,065 colonies from 23 faecal banks were screened for anti- Listeria
activity (Table 3). Direct antagonism of L. monocytogenes 10403S with distinct clear
zones of inhibition was seen in 443 colonies from 11 of the screened faecal bacterial
banks. Hazy zones of inhibition were observed in 1,126 colonies. The remaining 2,496
colonies did not demonstrate anti- Listeria activity under the conditions tested. Overall
1,569 colonies demonstrated activity against Listeria (clear distinctive zones or hazy
zones).

A

B

C

Fig.2 Representative pictures of plates showing results obtained for deferred
antagonism assays with gut-derived bacterial strains from 3 different faecal samples
using L. monocytogenes 10403S as the indicator strain. The gut derived- bacteria were
grown on agar and subsequently UV treated and overlaid with sloppy agar seeded with
L. monocytogenes. Plates were incubated overnight and examined for zones of
inhibition. (A) Only one colony in this faecal bank produced a clear, distinct zone of
inhibition. 17 colonies produced hazy zones of inhibition (not shown in picture) (B)
127 colonies from this faecal bank produced clear, distinct zones of inhibition. 9
colonies produced hazy zones (not shown in picture) (C) 168 colonies from this faecal
bank produced hazy zones of inhibition. 12 colonies produced clear, distinct zones of
inhibition (not shown in picture).
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Table 3. Number of colonies and different types of zones of inhibition observed in the
initial screening of the bacterial faecal banks.
Bank no.
102
104
105
107
110
111
113
117
119
121
122
123
126 stock 1
126 stock 2
128
129
130
131
132
133
134
136
175

No. of colonies
examined
135
180
141
192
168
142
179
236
227
249
157
302
266
190
122
142
144
191
94
142
132
190
144

No. of distinct
zones
53
13
0
0
0
121
127
0
1
0
0
0
0
0
0
0
1
2
0
2
7
12
104

No. of hazy
zones
67
38
45
0
0
0
9
0
17
0
70
156
266
139
11
49
7
84
0
0
0
168
0

TOTAL

4,065

443 (11%)

1,126 (28%)

Selection of strains for further investigation. In total, of the 1569
colonies that have shown anti- Listeria activity, 59 were chosen for further analyses.
For each faecal bank all active colonies were compared to each other so that the
maximum number of colonies showing different cell morphology and variety in the
zone of inhibition size and appearance were selected in order to maximize the number
of potentially different bacterial isolates and antimicrobials. The 59 strains were grown
from the 96 well stock plates in broth and streaked onto agar to ensure purity. Colonies
from pure cultures were regrown and were re-stocked. The anti-Listeria activity of
strains was re-investigated using deferred antagonism assays. Different types of zones
of inhibition were observed (Fig.3). These varied from clear distinctive zones of
inhibition, hazy zones of inhibition to a slight clearing in the agar just where the
bacterial spot had grown.
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A

B

C

41

40

47

20

55

5

57

C

Fig. 3 Representative pictures of the deferred antagonism assays that were carried out
to confirm the anti-Listeria activity of gut-derived bacterial strains. The gut derivedbacteria were grown on agar and subsequently UV treated and overlaid with sloppy
agar seeded with L. monocytogenes 10403S. Plates were incubated overnight and
examined for zones of inhibition. (A) – Clear, defined zones of inhibition, (B) - Hazy
zones of inhibition, (C) - Inhibition only within the area of the spot. The number in the
top left corner indicates the gut-derived isolate shown in the panel.

Identification of gut-derived strains. Gram stains revealed that all of the
strains under investigation were Gram-positive and cocci in shape. A combination of
two approaches was used to identify the gut-derived strains. At first the isolates were
identified with MALDI–TOF MS, which was carried out on fresh colonies and results
suggest that the majority of strains were Enterococcus (Table 4). This approach
identified 39 of the shortlisted isolates while the remaining 20 isolates were not
identified. The remaining isolates were putatively identified by sequencing part of the
16S rRNA gene. Overall 33 of the isolates were sequenced in order to confirm the
reliability of identification obtained by MALDI TOF MS (Table 4). 56 of the isolates
were identified as Enterococcus spp. while the remaining 3 isolates were identified as
Streptococcus spp.
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Table 4. Identification of the gut- derived isolates based on the results obtained from
combination of MALDI-TOF MS readings as well as the results obtained from the
partial 16S genome sequencing.
Strain
ID

Screening
ID
102.1.E3

Isolate ID obtained
from
MALDI –TOF MS
Enterococcus faecium

MALDI –
TOF MS
score
2.217

Isolate ID obtained
from partial 16S gene
sequencing
Enterococcus faecium

Accession number
of closest BLAST
homology
MH127510.1

32
53

102.1.F6

Enterococcus faecium

1.878

Enterococcus faecium

MH127529.1

12

102.2.D2

Enterococcus faecium

2.296

*

N/A

24

102.2.D6

Enterococcus faecium

2.056

*

N/A

64

102.3.C5

Enterococcus faecium

2.367

*

N/A

21

102.3.C9

Enterococcus faecium

2.245

*

N/A

20

104.5.A1

-

-

Enterococcus hirae

KY950612.1

18

104.5 G7

-

-

Enterococcus hirae

MF975716.1

5

104.5.A9

Enterococcus hirae

1.946

Enterococcus hirae

MF108171.1

51

104.5.H10

-

-

Enterococcus hirae

KY950612.1

48

111.1.A1

-

-

Enterococcus durans

MF357679.1

44

111.1.C1

-

-

Enterococcus faecium

KT598442.1

4

111.1.G1

-

-

Enterococcus faecium

KY129997.1

6

111.1.G11

-

-

Enterococcus faecium

MH127529.1

8

-

-

Enterococcus faecium

MF424775.1

45

111.1.H10
A
111.2.A11

Enterococcus faecium

2.041

*

N/A

42

111.2.A3

Enterococcus faecium

2.136

*

N/A

33

111.2.H6

-

-

Enterococcus faecium

KY129997.1

37

-

-

Enterococcus faecium

LC193724.1

49

111.3.A11
A
111.3.B2

-

-

Enterococcus faecium

KY129997.1

1

111.3.G7

Enterococcus faecium

2.181

*

N/A

71

111.3.H10

Enterococcus faecium

2.172

*

N/A

9

111.3.H2

Enterococcus faecium

1.991

*

N/A

40

113.1.A1

Enterococcus faecium

2.227

Enterococcus faecium

MF354616.1

72

113.1.D2

-

-

Enterococcus faecium

KY129997.1

46

113.1.F12

Enterococcus faecium

2.056

*

N/A

7

113.2.A1

Enterococcus faecium

2.369

*

N/A

3

113.2.A7

Enterococcus faecium

1.831

*

N/A

28

113.2.H8

Enterococcus faecium

1.996

Enterococcus faecium

CP019770.1

27

113.3.B8

Enterococcus faecium

1.952

*

N/A

10

113.4.A3

Enterococcus faecium

2.195

*

N/A

47

113.4.D8

Enterococcus faecium

2.049

*

N/A

17

113.4.H12

Enterococcus faecium

2.049

*

N/A

15

119.1.E5

Enterococcus faecium

2.422

Enterococcus faecium

MH127530.1

66

130.2.C1

1.357

Streptococcus mitis

LT707616.1

73

133.1.C7

Streptomyces
phaeochromogenes
-

-

Streptococcus mutans

LC193724.1

51

70

Streptococcus mutans

1.914

Streptococcus mutans

CP013237.1

54

133.2.A1
(A)
134.1.B6

Enterococcus faecium

2.318

Enterococcus faecium

KF25454.1

43

134.2.A11

Enterococcus faecium

2.001

Enterococcus faecium

KY962871.1

2

Enterococcus faecium

2.38

*

-

-

Enterococcus faecium

KY962897.1

60

134.2.A5
(A)
134.2.A7
(A)
134.2.E3

-

-

Enterococcus faecium

KT598442.1

58

134.2.E.9

Enterococcus faecium

2.049

*

N/A

39

134.3.A9

Enterococcus faecium

2.281

*

N/A

57

136.4.A9

-

-

Enterococcus avium

KP645382.1

29

136.4.B2A

-

-

Enterococcus faecium

MF357615.1

52

136.4.A11

-

-

Enterococcus faecium

LC193724.1

63

136.4.A1

-

-

Enterococcus faecium

KP645382.1

38

175.1.A5

Enterococcus faecium

1.595

Enterococcus faecium

MF357685.1

13

Enterococcus faecium

2.269

*

N/A

Enterococcus faecium

1.651

Enterococcus faecium

MH111696.1

Enterococcus faecium

1.982

*

N/A

61

175.1.C9
(A)
175.1.G7
(A)
175.1.H12
(A)
175.1.H2

Enterococcus faecium

1.631

Enterococcus faecium

MH111695.1

55

175.2.A1

Enterococcus faecium

1.862

*

N/A

31

Enterococcus faecium

2.11

*

N/A

36

175.2.C3
(A)
175.2.G9

Enterococcus faecium

2.364

*

N/A

16

175.3.B10

Enterococcus faecium

2.306

*

N/A

14

175.3.H10

Enterococcus faecium

2.084

*

N/A

34

175.3.A1
(A)

-

-

Enterococcus faecium

KY129997.1

62

11
41

(-) No match in the database, * 16S sequencing was not carried out for that strain, N/A
not applicable. Note: screening IDs were assigned based on the 96 well plate number
and well position that the strain was obtained from e.g. 102.1.E3 is a strain from faecal
bank 102, 96 well plate number 1, well E3.
The (A) in Screening IDs refers to stock A of that strain when more than one stock was
made.
Investigation of the nature of the antimicrobial compounds. Agar well
diffusion assays were carried out to investigate whether the antimicrobial activity is
primarily associated with the cells or if the antimicrobial is secreted into the growth
medium. The CFS and WCE from overnight cultures were prepared and examined for
their anti-Listeria activity in agar well diffusion assays. Differences were observed in
the zone sizes for CFS and WCE when different strains were compared (Fig.4). For
example, for samples 1 and 2 zones of inhibition were observed for both CFS and WCE,
but for sample 1 the zone for the CFS was bigger than the zone for the WCE, while the
opposite was the case for sample 2. The findings of the experiments presented in Table
52

5 have shown that the distinct zones of inhibition were observed for CFS from 45 of 59
isolates while zones were not observed for the other 14. For the 14 for which zones
were not observed for CFS, it is possible that the antimicrobial compound may not be
secreted into the medium at all, or is secreted but the concentration is too low to be
detected using the agar diffusion assay. It was noted that the WCE of 4 of the strains
(isolates 20, 18, 5, 73) demonstrated anti-Listeria activity whereas their corresponding
CFS did not demonstrate activity suggesting that in these cases the antimicrobial
compounds may be primarily cell-associated.

A

B

Fig.4 Representative pictures of agar well diffusion assays with (A) CFS and (B) WCE,
prepared from two gut-derived strains. Agar was seeded with 1% L monocytogenes
10403S, wells were bored in the agar to which either CFS or WCE from gut-derived
strains was added. Plates were incubated overnight at 37 C, after which they were
examined for zones of inhibition. Wells labelled 1= gut derived isolate 4, wells labelled
2 = gut derived isolate 15.
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Table 5. The pH of the cell free supernatants (CFS) extracted from the isolates and
results of a well diffusion assay carried out with CFS and whole cell extract (WCE)
from gut derived isolates, the zones were measured in (mm) including the size of the
well (5 mm).
Strain
ID

Screening
ID

Isolate ID

CFS pH

Zone size obtained
with CFS (mm)

32

102.1.E3

E. faecium

7

0

Zone size
obtained with
WCE (mm)
0

53

102.1.F6

E. faecium

7

0

0

12

102.2.D2

E. faecium

7

0

0

24

102.2.D6

E. faecium

7

0

0

64

102.3.C5

E. faecium

7

0

0

21

102.3.C9

E. faecium

7

0

0

20

104.5.A1

E. hirae

7

0

6

18

104.5 G7

E. hirae

7

0

6

5

104.5.A9

E. hirae

7

0

6

51

104.5.H10

E. hirae

7

hh

6

48

111.1.A1

E. durans

7

11

7

44

111.1.C1

E. faecium

7

9

9

4

111.1.G1

E. faecium

7

11

6

6

111.1.G11

E. faecium

7

11

7

8

E. faecium

7

10

7

45

111.1.H10
A
111.2.A11

E. faecium

7

11

7

42

111.2.A3

E. faecium

7

10

0

33

111.2.H6

E. faecium

7

9

7

37

E. faecium

7

9

9

49

111.3.A11
A
111.3.B2

E. faecium

7

9

6

1

111.3.G7

E. faecium

7

12

7

71

111.3.H10

E. faecium

7

11

7

9

111.3.H2

E. faecium

7

10

7

40

113.1.A1

E. faecium

7

7

9

72

113.1.D2

E. faecium

7

7

7

46

113.1.F12

E. faecium

7

8

7

7

113.2.A1

E. faecium

7

9

7

3

113.2.A7

E. faecium

7

8

8

28

113.2.H8

E. faecium

7

7

8

27

113.3.B8

E. faecium

7

8

8

10

113.4.A3

E. faecium

7

8

10

47

113.4.D8

E. faecium

7

11

0

17

113.4.H12

E. faecium

7

6

7

15

119.1.E5

E. faecium

7

11

15

66

130.2.C1

S. mitis

7

0

0

73

133.1.C7

S. mutans

7

0

7

70

133.2.A1
(A)
134.1.B6

S. mutans

7

0

0

E. faecium

7

13

14

54

54

43

134.2.A11

E. faecium

7

12

11

2

E. faecium

7

13

13

E. faecium

7

13

14

60

134.2.A5
(A)
134.2.A7
(A)
134.2.E3

E. faecium

7

13

14

58

134.2.E.9

E. faecium

7

11

15

39

134.3.A9

E. faecium

7

15

15

57

136.4.A9

E. avium

7

0

0

29

136.4.B2A

E. faecium

7

15

15

52

136.4.A11

E. faecium

7

12

6

63

136.4.A1

E. faecium

7

0

0

38

175.1.A5

E. faecium

7

7

8

13

E. faecium

7

7

7

E. faecium

7

7

7

E. faecium

7

7

9

61

175.1.C9
(A)
175.1.G7
(A)
175.1.H12
(A)
175.1.H2

E. faecium

7

7

7

55

175.2.A1

E. faecium

7

7

8

31

E. faecium

7

7

7

36

175.2.C3
(A)
175.2.G9

E. faecium

7

7

8

16

175.3.B10

E. faecium

7

7

7

14

175.3.H10

E. faecium

7

7

7

34

175.3.A1
(A)

E. faecium

7

7

8

62

11
41

hh- hazy halo, no clear define zone of inhibition.

Deferred antagonism assays to examine the spectrum of activity of gutderived strains. In order to investigate the inhibition spectrum of the 59 shortlisted
gut-derived isolates, deferred antagonism assays were carried out with 14 different
indicator strains. Fig. 5 illustrates representative images showing various images with
types of zone sizes observed in the test. Table 6 displays detailed results of the assay
with Gram-positive and Gram- negative indicator strains. The results showed that 57
out of 59 of the shortlisted gut-derived isolates inhibited L. monocytogenes 10403S
again confirming the anti-Listeria activity that was observed in the initial screen. The
remaining 2 isolates (isolates 66 and 73) did not produce zones. It should be noted that
those two isolates have previously confirmed anti-Listeria activity, but produced very
small hazy zones/halos of inhibition and have shown varied growth rates under the
experimental conditions used.
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The other Listeria strains that were tested were also inhibited by the 57 gut
isolates – it was noted that the zones of inhibition produced against L. monocytogenes
EGDe were closest in size to those produced against L. monocytogenes 10403S, smaller
zones were observed against L. monocytogenes F2365 and the least activity was
observed against L. monocytogenes LO28. It can be seen from the figure that
differences the antimicrobial activity varied greatly between various indicator strains.
The results obtained for L. monocytogenes F2365 showed that 46 of the isolates have
shown activity while 13 have not shown activity against this strain of Listeria. The
results acquired when using L. monocytogenes L028 have shown that 15 showed
activity while the remaining 44 have shown no activity. The results obtained when
using L. monocytogenes EGDe as an indicator strain have showed that 42 of the isolates
have shown activity against this indicator strain while the remaining 17 have shown no
activity. The results obtained when using L. innocua as an indicator strain established
that 50 of the isolates have demonstrated activity under the experimental conditions.
58 out of 59 strains also inhibited some of the other Gram-positive bacteria tested
(Enterococci, M. luteus, L. lactis) while no activity was observed for isolate 66. The
results obtained when using E. hirae as an indicator strain have showed that 38 have
shown activity against this indicator. 58 of the isolates have demonstrated activity when
using E. faecium as an indicator. The results obtained when using L. lactis HP as an
indicator revealed that 57 of the isolates produced zones of inhibition, with the majority
being small and hazy zones. 54 of the isolates have produced zones of inhibition when
using M. luteus as an indicator strain, again the majority of observed zones were small
and hazy. No activity was observed against B. subtilis and the Gram-negative bacteria
tested (S. enteritidis, E. coli, and P. aeruginosa). Fig. 5 shows a representative set of
results obtained for gut-derived strain number 29.
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A

F

L
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G
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Fig.5 Deferred antagonism assays showing the spectrum of activity of gut-derived
isolate number 29 against various indicator strains. Isolate 29 was grown overnight in
BHI broth, spotted onto BHI agar and incubated at 37 C overnight. Spot plates were
then UV treated and overlaid with 5 ml of sloppy agar seeded with 1% inoculum of the
following indicator strains: (A) L. monocytogenes 10403S, (B) L. monocytogenes
F2356, (C) L. monocytogenes EGDe (D) L. monocytogenes L028, (E) L. innocua, (F)
E. faecium (G) E. hirae (H) L. lactis HP (I) M. luteus, (J) Bacillus subtilis, (K) S.
aureus, (L) Salmonella enteritidis, (M) E. coli and (N) P. aeruginosa. The plates were
then incubated at 37 C for 18 hours and checked for zones of inhibition.
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102.1.E3

E. faecium

hh

-

-

-

hh

-

+

-

hh

+

-

-

-

-
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aeruginosa

104.5.A9
104.5.H10

E. hirae
E. hirae
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E. faecium

E. faecium
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-

-

-

-

-

-

-

-

-

-

E. coli

-

S. enteritidis

-

S.aureus

-

M. luteus
+

L. lactis HP
hh

B. subtilis
-

E. hiare
+

E. faecium
-

E. faecium

L. innocua
hh

102.1.F6
E. faecium

EGDe
-

102.2.D2
E. faecium

L028
-

102.2.D6
E. faecium

F2365
-

102.3.C5
E. faecium

10403S
hh

102.3.C9
E .hirae

Isolate ID
E. hirae

104.5.A1

number

104.5 G7

Sample

Table 6. Results of deferred antagonism assays that investigate the spectrum of activity of the 59 shortlisted isolates against Gram-positive indicator
strains; L. monocytogenes 10403S, L. monocytogenes F2365, L. monocytogenes L028, L. monocytogenes EGDe, L. innocua, E. faecium, E. hirae,
B. subtilis, L. lactis and M. luteus and Gram-negative strains S. aureus, S. enteritidis, E. coli and P. aeruginosa.
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42

45

8

6

4

44

48

51

5

18

20

21

64

24

12

53

32

Strain ID

58

60

62

2

43

54

70

73

66

15

17

47

10

27

28

3

7

46

72

40

9

71

1

49

37

134.2.E.9

134.2.E3

134.2.A7 (A)

134.2.A5 (A)

134.2.A11

134.1.B6

133.2.A1 (A)

133.1.C7

130.2.C1

119.1.E5

113.4.H12

113.4.D8

113.4.A3

113.3.B8

113.2.H8

113.2.A7

113.2.A1

113.1.F12

113.1.D2

113.1.A1

111.3.H2

111.3.H10

111.3.G7

111.3.B2

111.3.A11A

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

S. mutans

S. mutans

S. mitis

E. faecium
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+

+

+
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+

+

+
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-

-

-

-

-

-

59

14

16

36

31

55

61

41

11

13

38

63

52

29

57

39

175.3.A1 (A)

175.3.H10

175.3.B10

175.2.G9

175.2.C3 (A)

175.2.A1

175.1.H2

175.1.H12

175.1.G7 (A)

175.1.C9 (A)

175.1.A5

136.4.A1

136.4.A11

136.4.B2A

136.4.A9

134.3.A9

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. faecium

E. avium

E. faecium

+

+

+

+

+

+

+h

+

+

+

+

hh

+

+

hh

+

+

+

+h

+h

+

+

+h

+h

+h

+h

+h

-

+

+

-

+

-

-

-

-

-

-

-

-

-

-

-

-

+

+

-

+h

+

+

+

+

+

+

+

+

-

+

+

-

+

+

+

+

+

+

+

+

+

+

+

+

+

+h

+

-

+

+

-

+

+h

+h

+h

+h

+h

+h

+h

+h

+h

+h

+h

-

+

+

-

+

-

-

-

hh

-

-

hh

hh

hh

hh

hh

-

+h

+

-

+

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

+

+

+

hh

+

+

hh

hh

hh

hh

hh

hh

+

hh

-

hh

hh

hh

hh

hh

hh

hh

hh

hh

hh

hh

hh

hh

+

+

-

+

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(A)
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(+) Indicates a clear distinctive zone of inhibition, (+h) indicates a zone of inhibition with a hazy outline, (hh) indicates a
hazy halo around the bacterial growth without a clear distinctive zone of inhibition (-) indicates no zone of inhibition.
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The colony morphology, spectrum of activity and the sizes of the zones of
inhibition produced against specific indicator strains, the results obtained in MALDI-TOF
analysis and partial 16S rRNA sequencing as well as the results of well diffusion assay with
CFS and WCE of the shortlisted gut-derived isolates originating from the same faecal banks
were compared in detail in order to narrow down the number of isolates for further
investigation. Isolates displaying almost identical results were assumed to be the same and only
one of the set of isolates displaying a given set of characteristics was further shortlisted; e.g.
isolates 40, 46, 73, 28, 27, 10 and 17 from faecal bank 113 all displayed almost identical results
when overlaid with the indicator strains, so only one of those isolates (40) was shortlisted.
Isolates 72 and 47 also from faecal bank 113 produced much bigger clearer zones of inhibition
than the remaining isolates from that faecal bank (data not shown), but their zones of inhibition
were almost identical to each other so only one of those two isolates (72) was shortlisted. Based
on the data collected it was established that there are potentially two different types of bacteria
in faecal bank 113, isolates 40 and 72 were selected for further testing. Table 7 displays the
list of 17 gut-derived isolates selected for further investigation, 15 of which were identified as
Enterococci spp. and the remaining two were identified as Streptococcus spp.

Table 7. List of 17 shortlisted isolates selected for further testing based on the results obtained
by comparison of cell morphology, spectrum of activity, bacterial identity and the results of
well diffusion assays with CFS and WCE.

Strain ID
32
12
20
18
48
4
40
72
15
66
73
54
43
57
52
29
38

Screening ID
102.1.E3
102.1.D2
104.5.A1
104.5.G7
111.1.A1
111.1.G1
113.1.A1
113.1 D2
119.1. E5
130.2.C1
133.2.A1A
134.1.B6
134.2.A11
136.4.A9
136.4.A11
136.4.B2
175.1.A5
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Identity
E. faecium
E. faecium
E. hirae
E. hirae
E. durans
E. faecium
E. faecium
E. faecium
E. faecium
S. mitis
S. mutans
E. faecium
E. faecium
E. avium
E. faecium
E. faecium
E. faecium

Cross immunity deferred antagonism assays. Cross immunity deferred
antagonism assays with a known enterocin A producer, E. faecium DPC 6482, and a known
enterocin B producer, E. faecium EM3-42-BC-1, were carried out in order to investigate if any
of the 15 short-listed gut-derived isolates identified as Enterococcus spp. produced either of
these bacteriocins. The main principle of this experiment is the fact that any bacterium
producing a given bacteriocin is immune to it. Therefore, if cross immunity between shortlisted
gut isolates and known enterocin producers were observed it could be deduced that the gut
strain is likely to produce that particular bacteriocin.
Fig. 6 Representation of the results obtained from this experiment. The complete set
of data collected from this experimental approach can be seen in Table 8.
A

C

B

D

Fig.6 A representative figure of the cross-immunity deferred antagonism assays. (A) Enterocin
A producing strain overlaid with L. monocytogenes 10403S showing a distinct zone of
inhibition. (B) Enterocin A producer overlaid with itself, showing no zone of inhibition and
demonstrating immunity to enterocin A. (C) Enterocin A producer overlaid with a gut derived
isolate, a zone of inhibition indicates lack of immunity and suggests that the peptide produced
by the indicator gut strain is not enterocin A. (D) Enterocin A producer overlaid with a gutderived isolate, a lack of zone of inhibition suggests that the gut strain produces enterocin A.
The data collected shows that the cross-immunity experiments suggest that 4 of the
15 short-listed Enterococcus (gut-derived strains 15, 54, 43 and 29) are likely to produce
enterocin A and B, i.e., no zones of inhibition were produced when the gut strains were overlaid
with the enterocin A and B producers (results in Table 9), additionally no zones were produced
when the enterocin A and B producers were overlaid with the gut-derived isolates (results in
Table 8) suggesting immunity to the produced antimicrobials. A total of 11 isolates did not
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produce results indicative of immunity; i.e., produced zones of inhibition when overlaid with
enterocin A and B producers. It was noted that gut-derived isolates 18 and 20 are sensitive to
enterocin A and B (Table 8) but the enterocin A and B producers are immune to the
antimicrobial(s) produced by isolates 18 and 20 (Table 9).
Table 8. Cross immunity deferred antagonism assay carried out with an enterocin A producing
E. faecium DPC 6482 and enterocin B producing E. faecium EM342-BC-1 spotted onto BHI
agar overlaid with gut- derived strains, zone sizes measured in mm.

DPC 6482
EM342-BC-1

32
27
30

12
26
30

20
25
29

18
26
28

48
25
27

Gut-derived isolate number
4
40 72 15 54 43
26 27 23
0
0
0
30 30 28
0
0
0

57
18
20

52
24
26

29
0
0

38
23
28

Table 9. Cross immunity deferred antagonism assay carried out with gut-derived isolates
spotted onto BHI agar and overlaid with enterocin A producing E. faecium DPC 6482 and
enterocin B producing E. faecium EM342-BC-1 zones of inhibition measured in mm.
Strain
ID
32
12
20
18
48
4
40
72
15
54
43
57
52
29
38

Screening
ID
102.1.E3
102.2D2
104.5.A1
104.5.G7
111.1.A1
111.1.G1
113.1A1
113.1.D2
119.1.E5
134.1.B6
134.2.A11
136.4.A9
136.4.A11
136.4.B2
175.1.A5

Isolate ID
E. faecium
E. faecium
E. hirae
E. hirae
E. duranus
E. faecium
E. faecium
E. faecium
E. faecium
E. faecium
E. faecium
E. avium
E. faecium
E. faecium
E. faecium

Indicator strain.
E. faecium DPC 6482
13
13
0
0
18
16
11
13
0
0
0
0
19
0
0

Indicator strain
E. faecium EM342-BC-1
13
12
0
0
18
18
11
21
0
0
0
0
26
0
12

Since a number of the gut-derived isolates selected for further experimentation
were obtained from the same faecal banks and their identities were confirmed to be the same
by either 16S rRNA sequencing or MALDI-TOF sequencing, an additional test was carried out
in order to reduce the possibility of shortlisting two identical isolates. A deferred antagonism
assay was carried out with the gut- derived isolates from the same faecal sample where each
strain was spotted onto agar and overlaid with the other strain(s). Again the main principle
behind this experiment was the fact that if two isolates were identical they should be immune
to each other’s antimicrobial agents (Mélançon and Grenier, 2003). As can be seen in Table
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10 the results suggest that strains 32 and 12 isolated from the same faecal bank number 102 are
likely to be identical. The results are visualized in Fig.7 and show that zones of inhibition were
not observed when the isolates were overlaid with each other, while antagonistic activity was
observed when the isolates were overlaid with a sensitive indicator strain of E. faecium. Strains
48 and 4 have also demonstrated cross-immunity, however, those gut-derived isolates were
identified as being different (E. durans and E. faecium) so both were retained for further
investigation. Similarly, isolates 43 and 54 showed cross-immunity. However, at the time the
assay was carried out experiments to establish the identity of isolate 54 were still underway
(described in Chapter 1) so both isolates were retained for further investigation. At this stage
the total number of the shortlisted isolates was reduced from 17 to 16. Strain 32 was eliminated
from further investigation.

A

B

C

D

Fig.7 A representative figure showing the results of deferred antagonism cross immunity
assays. (A) Gut-derived isolate 12 overlaid with gut-derived isolate 32. A zone of inhibition
was not observed. (B) Gut-derived isolate 32 overlaid with gut-derived isolate 12 also from
faecal bank 102. A zone of inhibition was not observed.
(C) A positive control showing that isolate 12 produces a zone of inhibition when overlaid with
Enterococcus faecium. (D) A positive control showing that isolate 32 produces a zone of
inhibition when overlaid with Enterococcus faecium.
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Table 10. Results of a cross immunity assay of faecal isolates derived from the same faecal
banks. Faecal isolates were grow in 10ml of fresh BHI broth overnight at 37°C. 10 L aliquots
of each of the cultures were then spotted onto fresh BHI agar and were incubated overnight at
37°C. The plates were then UV treated for 30 minutes in order kill any viable cells. UV treated
plates were overlaid with 5ml of fresh 0.7% (w/v) agar sloppy BHI agar seeded with 1%
inoculum of a faecal isolate originating from the same faecal bank. The plates were incubated
overnight at 37°C and zones of inhibition were recorded. Zone sizes in (mm) include the size
of the well (5mm)
Spotted strain
Screening
ID

Strain in the overlay

Strain
ID

Sample ID

Indicator
Screening ID

Indicator
strain ID

Indicator
ID

102.1.E3

32

E. faecium

102.1.D2

12

E. faecium

Zone
size
0

102.2.D2

12

E. faecium

102.1.E3

32

E. faecium

0

104.5A1

20

E. hirae

104.5.G7

18

E. hirae

13

104.5.G7

18

E. hirae

104.5.A1

20

E. hirae

hh

111.1.A1

48

E. durans

111.1G1

4

E. faecium

0

111.1.G1

4

E. faecium

111.1.A1

48

E. durans

0

113.1.A1

40

E. faecium

113.1.D2

72

E. faecium

hh

113.1.D2

72

E. faecium

113.1.A1

40

E. faecium

17

134.1.B6

54

E. faecium

134.2.A11

43

E. faecium

0

134.2.A11

43

E. faecium

134.1.B6

54

E. faecium

0

136.4.A9

57

E. avium

136.4.A11

52

E. faecium,

0

136.4. A11

52

E. faecium

136.4.A9

57

E. avium

28

136.4A9

57

E. avium

136.4.B2

29

E. faecium

0

136. 4. B2

29

E. faecium

136.4.A9

57

E. avium

21*

136.4 A11

52

E. faecium

136.4.B2

29

E. faecium

23

136.4.B2

29

E. faecium

136.4.A11

52

E. faecium

29

(hh) Represents a hazy halo around the colony where no clear definite zone of inhibition is
present, (*) represents a zone of inhibition with no definite outline.

Deferred antagonism assays with the final 16 short-listed strains in the
presence of proteinase K. In order to investigate if the compounds responsible for
antimicrobial activity were protein in nature, deferred antagonism assays were carried out in
the presence of proteinase K. Fig.8 shows the results obtained for one gut-derived isolate (strain
no. 48).
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A

B

Fig. 8 A representative image of the results obtained for the protease assay with gut-derived
strain no. 48. The strain was spotted onto BHI agar in duplicate, grown overnight and UV
treated. 2µL of proteinase K was spotted adjacent to the bacterial spot on one plate, the plate
was incubated at 37°C for 1 hr and then overlaid with sloppy (0.7%) BHI agar seeded with 1%
L. monocytogenes 10403S incubated at 37°C for 18 hours. (A) Control showing the antiListeria activity of gut strain no.43 (i.e. when no enzyme is present). (B) Proteinase K was
spotted adjacent to the bacterial spot (indicated by the black spot).

For 10 of the 16 shortlisted strains the zones of inhibition were measurably
reduced by proteinase K when overlaid with L. monocytogenes 10403S. The effect of
proteinase K on the remaining 6 strains could not be conclusively determined by the assay, as
the zones of inhibition obtained were small and/or hazy when using L. monocytogenes 10403S
as an indicator strain. As the cross-immunity deferred antagonism assays showed that large
zones of inhibition were observed when gut-derived isolates were tested against the enterocin
A producers E. faecium DPC 1146 / E. faecium DPC 6482 (data not shown), the proteinase K
assays were also carried out using those strains as indicators. These assays revealed that the
zone of inhibition for one additional strain (strain 12) was visibly reduced by the presence of
proteinase K. Overall a total of 11 out of 16 gut-derived isolates were confirmed to produce
antimicrobials that are peptide in nature. The zones of inhibition produced by the remaining 5
isolates were too small to allow the observation of reduction of zone sizes in the experimental
conditions used as can be seen in Table 11.
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Table 11. Results obtained from protease assay with 16 shortlisted gut-derived isolates. The
strains were spotted onto BHI agar in duplicate, grown overnight and UV treated. 2µL of
proteinase K was spotted adjacent to the bacterial spot on one plate, the plate was incubated at
37°C for 1 hr and then overlaid with sloppy (0.7%) BHI agar seeded with 1% L. monocytogenes
10403S or E. faecium DPC 6482/ 1146 and incubated at 37°C for 18 hour
(+)

Strain ID
12
20
18
48
4
40
72
15
66
73
54
43
57
52
29
38

Screening
ID
102.1.D2
104.5.A1
104.5.G7
111.1.A1
111.1.G1
113.1.A1
113.1 D2
119.1. E5
130.2.C1
133.2.A1
134.1.B6
134.2.A11
136.4.A9
136.4.A11
136.4.B2
175.1.A5

Isolate ID
E. faecium
E. hirae
E. hirae
E. durans
E. faecium
E. faecium
E. faecium
E. faecium
S. mitis
S. mutans
E. faecium
E. faecium
E. avium
E. faecium
E. faecium
E. faecium

Reduction of antimicrobial activity
by proteinase K
+
ND
ND
+
+
+
+
+
?
?
+
+
?
+
+
+

Indicates a positive results i.e. a visible reduction of the size of the zone of inhibition by
proteinase K, ND- the effect of proteinase K on the zone size could not be determined.
PCRs with primers for enterocin, duracin and hiracin genes. PCRs with a
number of enterocin, duracin and hiracin specific primers was carried out. The results obtained
for strains 15, 43, and 29 are in agreement with the results obtained in the cross immunity assay
with enterocin A and B producers (Table 8 and 9) indicating that these 3 isolates have the
genes needed for synthesis of enterocin A and enterocin B. Overall, isolates 15, 29, 40 and 43
were positive for enterocin A genes, while testing of isolates 12, 15, 29, 43, 52 and 54
confirmed the presence of enterocin B genes (data not shown). One of the main limitations of
the PCRs was the lack of positive controls; the enterocin A and enterocin B PCRs were the
only two PCRs which had positive controls. Due to the lack of controls, the remaining PCRs
could not be optimized despite careful primer design as well as continuous efforts to optimize
the protocols, i.e., running the PCRs with a variety of annealing temperatures. Taking into
account that a number of PCRs including enterocin P, enterocin L50A, enterocin L50B, duracin
A, duracin B, duracin Q as well as hiracin JM79 were not optimized and despite obtaining faint
bands, the presence of genes of interest was not confirmed.
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DISCUSSION
A total of 23 bacterial banks were created from 23 human faecal samples obtained
from 22 donors. A number of various colony types was observed while preparing the faecal
banks, those varied from small white pin point colonies, single white and beige colonies,
“fuzzy” type of colonies to irregularly wrinkled white colonies, colonies varied in size and
shape from circular to irregular, differences in color of the colonies were also observed varying
from semi- transparent, white, beige, yellow to red (data not shown). While some of the faecal
banks showed a variety of colony morphologies, others contained colonies that were mostly
similar in appearance. As reported by several studies in the literature (Harmsen et al. 2002;
Sender et al. 2005; Thiel & Blaut 2005) , the number of bacterial cells per gram of faeces
varies between 10 10 to 10 11 CFU/g of dry/wet faeces. The number of bacterial cells recovered
from the faecal samples in the current study was lower at around 10 7 CFU/g of faeces. This
may be attributed to the fact that the faecal banks were not fresh and have been previously
thawed out and frozen a number of times. Literature shows that significant statistical
differences should not be observed when comparing the microbiota recovered from fresh faecal
samples vs. samples frozen for long term storage (Fouhy et al. 2015; Kruse et al. 2015).
However, it has also been reported that the time between fecal sample collection and its
subsequent freezing for long term storage during which the samples are stored at refrigerator
temperature can be critical to the microbial composition prior its freezing (Choo et al. 2015).
Resuscitation of cells post freezing can also be lower when comparing to fresh samples
especially with respect to less abundant organisms sensitive to freezing such as
Bifidobacterium (Fouhy et al. 2015). All of the above can contribute to the fact that the major
bacterial species recovered in the initial screening were identified as Enterococci as those are
considered to be easy to culture in laboratory conditions. It should also be considered that the
experimental conditions used for screening is not optimal for all of the bacteria present in the
faecal banks. The incubation conditions and media used in the study could potentially be the
limiting factor for growth of some of the faecal isolates, especially in light of the fact that it is
estimated that only 10-20 % of the gut microbiota are cultivable in laboratory conditions
(Eckburg et al. 2005). Additionally the experimental design used in the initial screening was
limited to the number of colonies which could be picked off the plate. This could have
potentially lead to missing/not picking up colonies showing activity against L. monocytogenes.
Use of a robotic colony picker would allow for greater precision and could end up with picking
up a higher number of isolates showing antagonistic activity. However, due to the nature of the
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samples the initial screening was carried inside an anaerobic hood which did not allow for the
use of a robot.
The bacterial banks were screened for antagonistic activity against L.
monocytogenes 10403S. Major differences were observed in the activity of the faecal isolates
from different faecal banks (Table 3). The fact that the majority (61%) of the gut derived
isolates did not show any activity in the experimental conditions used for screening does not
necessarily mean that those isolates were not producing any antimicrobials. Literature
frequently shows that the production of antimicrobials such as bacteriocins is often inducible
in specific environmental conditions such as competition with other microorganisms present
in the specific environmental niche; i.e., co-culture with particular microorganisms, or the
presence of certain autoinducer peptides can induce bacteriocin production (MaldonadoBarragán et al. 2013). Lactic acid bacteria (LAB) often have an optimum temperature range at
which the bacteriocin production may be induced (Cintas et al. 1995; Mortvedt-Abildgaa et al.
1995; Nilsen et al. 1998 ). This principle also applies to pH, as an optimal pH is regularly
required in order for a bacteriocin to be produced (Biswas et al. 1991; Mortvedt-Abildgaa et
al. 1995). It should be noted that only one indicator strain was used in the current study meaning
that only the bacteria producing anti- Listeria compounds were picked out. It is possible that
the gut isolates could produce antimicrobials active against other enteric pathogens but were
not the focus of this study. The current study screened 4,065 colonies, of which only 443
screened colonies produced clear distinctive zones of inhibition against the indicator strain. An
additional 1,126 colonies have produced hazy zones of inhibition with a total of 1569 (39%)
of isolates displaying some level of antagonistic activity against the indicator strain. Whilst this
appears as a relatively small proportion of the isolates, it is actually much higher than the
relative (%) of active isolates found in similar studies. In contrast, a study carried out by O’Shea
et al. (2009), which included over 40,000 colonies of mammalian intestinal origin, only 278
demonstrated antagonistic activity against the indicator strains L. innocua DPC3572 and L.
bulgaricus LGM 6001; i.e. 0.695% of the screened colonies. Similarly, in a study carried out
by Lakshminarayanan et al. (2012), where 70,000 colonies from 266 samples of faeces of
elderly subjects were screened, activity was recorded for 273 screened isolates, representing
0.4% of all screened isolates. For this study, L. innocua DPC3572 was one of several indicators
used and was employed as an indicator in the screening of 123 samples. Another similar study
by Al-Seraih et al. (2017) performed at a smaller scale, screened 500 colonies isolated from
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infant faeces and found 70 isolates active against L. innocua ATTC51742, which represent 14
% of all the colonies screened.
Anti-Listeria bacteriocins have previously been reported to be isolated from
bacterial strains of human gastrointestinal origin; i.e. Lactobacillus salivarius UCC118
producing bacteriocin Abp118 active against L. monocytogenes (Corr et al. 2007) or
Bifidobacterium BIR-0304, BIR- 0307 and BIR-0349 isolated from human faeces, with a
broad spectrum of activity isolated by Collado et al. (2005). Anti-Listeria activity of
bacteriocins produced by members of the Enterococcus spp. isolated from humans has also
been reported (Al Atya et al. 2015; Birri et al. 2010; Birri et al. 2013; İspirli et al. 2015).
Additionally metagenomic analysis of the human gut microbiota showed that Enterococcus
have between one and 12 bacteriocin related genes in their genomes (Drissi et al. 2015). It is
possible that the reason that the majority of the isolates with anti-Listeria activity were
Enterococcus may be due to the fact that they are easy to culture and/or they produce
antimicrobials such as class IIa bacteriocins with very potent anti-Listeria activity. Bacteria
that produce antimicrobials with low activity may not have been detected by our screen.
Enterococci have also been shown to produce more than one bacteriocin simultaneously.
Vandera et al. (2018) examined 11 isolates of E. faecium four of those isolates were shown to
produce enterocin A, two were shown to produce two enterocins namely enterocin A and
enterocin B, while the remaining five isolates were shown to produce 3 bacteriocins enterocin
A, enterocin B and enterocin P. Similar findings were observed by Aspri et al. (2017) who has
examined 3 E. faecium isolates all of which have shown production of two bacteriocins
enterocin A and enterocin B. Additionally Du et al. (2017) has shown that E. durans 152 can
produce two bacteriocins duracin 152A (a derivative of enterocin L50A) and enterocin L50B.
The main objective when performing the well diffusion assay with both the CFS
and the WCE was to identify the nature of the antimicrobial compounds synthetized by the gutderived isolates. The main principle behind the experimental set up was based on the idea that
if the antimicrobial compound is cell associated it remains bound to the cell wall of the
producing cell, however if the nature of the antimicrobial is extracellular it is secreted into the
surrounding growth medium (Barbour and Philip, 2014). Thus if the antimicrobial was excreted
to the surrounding growth medium, higher levels of antimicrobial activity should be observed
in the CFS of the gut isolate. On the other hand, if the antimicrobial compound is cell bound it
is not readily extracted into the surrounding medium, thus the zone of inhibition produced by
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the CFS would not be as great. In such cases the antimicrobial is “stripped” off the cell by
shaking the cells for 3 hr in 70%IPA0.1% TFA and the resulting zone of inhibition produced
by the WCE would be greater in size. The results of the current study have shown that the CFS
of 43 of the gut-derived isolates have shown antagonistic activity against Listeria suggesting
that the antimicrobial produced by those isolates was excreted into the surrounding media. The
WCE of 5 of the isolates has demonstrated anti-Listeria activity while the CFS of the
corresponding isolates has shown no activity suggesting that the antimicrobial produced by
those strains is primarily cell bound.
As reported in the literature, the bacteriocins and bacteriocin like antimicrobials
produced by Gram-positive bacteria often have a narrow spectrum of activity normally with
activity against other Gram-positive bacteria (Jack et al. 1995). A few reported bacteriocins
are capable of inhibiting Gram-negative bacteria. Examples of such bacteriocins include;
plantaricin 35d synthetized by Lactobacillus plantarum showing antagonistic activity against
Aeromonas hydrophila (Messi et al. 2001; Parada et al. 2007), the bacteriocin thermophylin,
synthetized by Streptococcus thermophilus showing antagonistic activity against Yersinia
enterocolitica, E. coli, Yersinia pseudotuberculosus, S. typhimurium as well as Gram-positives
such as L. monocytogenes and a number of Bacillus spp. (Ivanova et al. 1998; Parada et al.
2007) and bacteriocin ST151BR synthetized by L. pentosus ST151BR active against
Pseudomonas aeruginosa, E. coli and Gram- positive L. sakei and L. casei (Parada et al.
2007; Todorov & Dicks 2004). The results obtained in this study suggest that the isolates have
a narrow spectrum of activity against Gram–positive bacteria, which is a common trait of class
II bacteriocins, including the many enterocins produced by Enterococcus spp. (Jack et al.
1995). A number of enterocins have been reported to show a narrow spectrum of activity.
Enterocin produced by E. faecium FAIR-E198 has shown antimicrobial activity against L.
monocytogenes, while activity was not reported against B. cereus or S. aureus (Nascimento et
al. 2010). Similar findings are documented by Ennahar & Deschamps (2000) where enterocin
A produced by E. faecium EFM01 has shown activity against 13 L. monocytogenes, with
significant inhibition of L. sake and enterococcal strains and a relatively low activity against
Pediococcus strains with no activity against S. aureus or Leuconostoc strains. Al-Seraih et al.
(2017) has shown that the enterocins isolated from infant faeces had a narrow spectrum of
activity. Antagonistic activity was recorded against Gram-positive bacteria including Listeria,
Clostridium, Bacillus while antagonistic activity was not observed against S. newport, S.
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heidelberg, E. coli and P. aeruginosa. Nes et al. (2014) reviews enterococcal bacteriocins, their
activity and contribution to niche control.
Lactic acid bacteria are known for production of bacteriocins as well as specific
immunity proteins, which deliver self-protection from the toxic effects of the bacteriocins they
produce. The production of those proteins can also deliver cross-immunity against associated
bacteriocins (Mélançon and Grenier, 2003). This trait was observed in a number of gut
delivered strains under investigation, conferring cross immunity not only to enterocin A and
enterocin B producers in 4 gut derived isolates but also to each other in some cases, allowing
for shortlisting of the isolates.
A deferred antagonism assay was performed with addition of proteinase K in order
to investigate if any of the antimicrobials produced by the gut-derived isolates were peptide/
protein in nature. Sensitivity to proteolytic enzymes indicates that the antimicrobials are protein
in nature. The bacteriocins synthetized by LAB are often completely deactivated by proteases
(Kumar et al. 2010). The current study shows that the antimicrobials produced by 11 out of 16
gut-derived isolates were inactivated by proteinase K suggesting that those were peptide in
nature. Inactivation of enterocins has been previously shown in a study carried out by Kumar
et al. (2010) where enterocin LR/6 isolated from E. faecium LR/6 isolated from rhizosphere
was found to show sensitivity to proteolytic enzymes such as proteinase K. Similar findings
were shown in a study carried out by Liu et al. (2008) were Enterococcus spp. producing
enterocin E- 760 isolated from caecum of boiler chickens showed sensitivity to proteinase K.
Similarities were also observed by O’Shea et al. (2009) where E. faecium DPC6482 isolated
from neonate faeces demonstrated sensitivity to proteinase K.
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CONCLUSIONS
A total of 4,065 colonies from 23 faecal bacterial banks were screened for antiListeria activity. Overall 1,569 (39%) colonies have demonstrated various levels of
antagonistic activity against L. monocytogenes, whereas 2,496 (61%) colonies did not show
any activity under the experimental conditions used. The isolates showing activity were then
shortlisted to 59 based on the size and appearance of the zone of inhibition and its size, colony
morphology as well as the faecal bank it ordinated from. The identity of the 59 gut-derived
strains with anti-Listeria activity has been established. The results of the 16S rRNA gene
sequencing, MALDI-TOF, deferred antagonism assays (against a variety of indicator strains),
well diffusion assays with CFS and WCE suggested that there were 17 different strains amongst
the 59 gut-derived isolates. A cross immunity deferred antagonism assays of faecal isolates
originating from the same faecal bank allowed for further shortlisting of the gut-derived
isolates from 17 to 16 based on the basis that two isolates were cross-immune. Deferred
antagonism assays with proteinase K suggested that the anti-Listeria activity in 11 of the 16
strains was likely to be due to an antimicrobial peptide production. The results of the cross
immunity assays and PCRs have shown that 4 of the 16 strains seem to have the genes
responsible for production of enterocin A while 6 tested positive for presence of genes
responsible for production of enterocin B. The data collected to date suggests 10 of the 16 short
listed gut -derived isolates may potentially produce novel bacteriocins or perhaps variants of
already known enterocins.
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Chapter 2

Further investigation of the anti-Listeria monocytogenes activity
of selected human gut derived bacteria
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INTRODUCTION
Ensuring a safe food supply is a constant challenge for the food industry. The use
of antimicrobial peptides such as bacteriocins produced by LAB, which have the ability to
target common foodborne pathogens without causing any adverse effects and ease of their
digestion have received attention (Cleveland et al. 2001; Mills et al. 2011). Bacteriocins have
a wide range of applications in the food industry, they can be used as bio-preservatives in foods
either by themselves or can be combined with other preservation methods; i.e., hurdle
technology (De Vuyst and Leroy, 2007; Perez et al. 2014). Currently there are only two
bacteriocins, which are available for commercial use in food preservation, those are nisin
(Nisaplin, Danisco) and pediocin PA1 (MicrogardTM, ALTA 2431, Quest) (Simha et al.
2012), meaning that there is a need for the discovery of new highly active and relatively cheap
bacteriocins, which can be used as food preservatives.
Enterococcus spp. are known for their production of enterocins, which include a
varied group of bacteriocins in relation to both their spectrum of activity and their classification
(Egan et al. 2016). The majority of LAB are considered as generally regarded as safe (GRAS)
and can be incorporated into food, however, in the case of bacteriocinogenic enterococci, there
are safety concerns (Barlow et al. 2007). Bearing those concerns in mind, the use of purified
enterocins for food applications is considered as a safer option than using the producing strains
(Silva et al. 2018). There are a number of novel food technology developments which can
employ the use of enterocins in food preservation. Bioactive food packaging has a potential
application where bacteriocins, or bacteriocin producing strains, can potentially be integrated
into the packaging itself, which acts as an anti-spoilage measure and can significantly extend
the shelf life of the product (Castellano & Vignolo 2006; Parada et al. 2007). This can be
applied to already established packaging materials. The effectiveness of such packaging has
been demonstrated by Liserre et al. (2002), where a bacteriocin-producing Lactobacillus sake
has been applied to modified atmosphere packaging (MAP). Similarly, bioactive packaging
with nisin has shown a reduction of LAB in sliced ham and cheese in MAP packaging. It has
also been observed that the packaging reduced the numbers of L. innocua by ~2 logs in both
cheese and ham and S. aureus by ~1.5 log in cheese and ~ 2.8 logs in ham, with comparable
results obtained when vacuum packing the products (Scannell et al. 2000), thus suggesting
great potential for commercialization of bioactive packaging. Comparably, Lactobacillus
curvatus CRL705 isolated from dry cured sausage, producing lactocin 705 and lactocin AL705,
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have decreased the growth of Bacillus thermosphacta and L. innocua in vacuum packed meat
discs (Castellano and Vignolo, 2006).
Biofilm formation is an on-going issue in the food-processing environment and is
of concern to the food industry as it can often cause contamination of the food being processed
on a production line. Biofilms are often formed in areas such as stainless steel processing
equipment, conveyer belts and storage area surfaces. Listeria biofilms are difficult to remove
and, if undetected, allow the bacterium to contaminate manufactured food product (Gandhi &
Chikindas 2007) and potential spread of a foodborne disease (Wong, 1998). Bacteria growing
in a biofilm often display higher levels of resistance to unfavorable environments such as heat
or sanitizers (Gandhi & Chikindas 2007; Pan et al. 2006; Van der Veen & Abee 2011).
Naturally occurring biofilms like those found in the food industry are often composed of mixed
bacterial species. Those have been shown to have a greater resistance to cleaning agents and
sanitizers (Bremer et al. 2001; Carpentier & Chassaing 2004). A significant reduction of
Listeria biofilm on stainless steel by enterocin B3A-B3B produced by a gut-derived
Enterococcus faecalis B3A-B3B has been shown by Al-Seraih et al. (2017), suggesting that
there is a potential for the development of novel anti-biofilm cleaning sprays with a view to
application in the food industry and prevention of product contamination.
The aim of this study was to further examine the inhibitory activities of gut-derived
isolates against L. monocytogenes 10403S. They were examined in broth co-culture
experiments, in food models and their ability to inhibit biofilm formation on stainless steel was
also investigated.
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MATERIALS AND METHODS
Broth based co-culture experiment. All shortlisted gut-derived isolates
identified as Enterococcus spp. and L. monocytogenes 10403S were grown overnight in BHI
broth at 37 C. 1 mL of each overnight culture was centrifuged and washed in sterile ¼ strength
Ringers’ solution. Co-culture experiments and controls were set up in 10 mL volumes of BHI
broth with 100µL of washed bacterial cells of L. monocytogenes 10403S and selected gutderived isolate combined in each tube. Growth controls were set up for every experiment i.e.
one tube containing L. monocytogenes 10403S alone and tubes containing the individual gutderived isolates only. A positive control was set up with a known enterocin A producer
Enterococcus faecium DPC 6482. All cultures were incubated at 37 C and aliquots removed,
serially diluted and plated on both BHI and Listeria Selective Agar Oxford Formulation
(Oxoid) (LSA) at T=0 hr, T=8 hr and T=24 hr. Plates were incubated at 37 C for 48 hr after
which they were counted. Plates were re-incubated and counted again after 72 hr in case there
was any further growth on them. Plate counts were performed on washed cells to determine
the initial inocula.
Food trials. Dairy products; (Tesco Everyday Value French brie, Tesco soft
cheese, Charleville Freshly Crafted Select Red Cheddar, Avonmore cottage cheese, Greek
Cheese Tesco Feta and Yoplait natural yoghurt) were purchased from a local supermarket in
Cork city and were analyzed as follows: a 50 g aliquot of brie cheese was aseptically weighed
out and transferred into a sterile stomacher bag (Seward) inside a laminar flow hood. 100 mL
of sterile PBS, i.e., a 1:2 dilution of cheese was added, the bag was sealed and the contents
were homogenized in a Tekmar Stomacher Lab Blender STO 80 for 5 min at the maximum
speed. Subsequently the cheese homogenate was transferred into sterile 50 mL tubes and
washed L. monocytogenes 10403S cells (1% inoculum, i.e. initial inoculum of ~ 107 CFU/mL)
was added and vortexed for 1 min. (The L. monocytogenes 10403S cells were washed in the
manner described previously. Briefly 1 mL of L. monocytogenes 10403S overnight culture was
centrifuged at 13,000 rpm for 5 min, the supernatant was then removed and the pellet was resuspended in 1mL of sterile ¼ strength Ringers solution). 900 L samples were taken from the
inoculated cheese homogenates and serially diluted in 900 L sterile ¼ strength Ringers
solution). Then 10 L aliquots of each dilution 10 -1 to 10-9 were spotted onto LSA agar cheese
homogenate samples were then immediately placed in a 37 C incubator and were incubated
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for 3 hr in total, with 100 L samples removed, serially diluted and 10 L aliquots of diluted
sample spot plated onto LSA. Counts performed at T=1 hr and T= 3 hr. The LSA plates were
incubated at 37 C for 48 hr. plate counts were then obtained and CFU/ mL were calculated.
The same protocol was used for number dairy products. The dilution factor used for various
cheeses was dependent on the texture and matrix of each cheese. Natural yogurt and soft cheese
were diluted 1:1 with sterile PBS solution; cheddar cheese, cottage cheese and feta cheese were
diluted 1:3 with sterile PBS solution. The experimental set up is displayed in (Table 1) The
CFS and WCE were prepared as previously outlined (Chapter 1) and their anti-Listeria
activity was confirmed by carrying out a well diffusion assays.
Table 1. The experimental set-up of the model food trials.
Tube contents

Comment

3 mL of cheese homogenate inoculated with 1% L.
monocytogenes.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L sterile BHI broth.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L 70%IPA0.1%TFA.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L of CFS from a known
Enterocin A producer.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L of WCE from a known
Enterocin A producer.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L of CFS from isolate 15.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L of WCE from isolate 15.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L of CFS from isolate 43.
3 mL of cheese homogenate inoculated with 1% L.
monocytogenes + 100 L of WCE from isolate 43
3 mL of uninoculated homogenized cheese sample.

Negative control to examine the growth of L. monocytogenes in
the food.
Negative control for test samples with added CFS.
Negative control for test samples with added WCE.
Comparison sample.

Comparison sample.

Test sample.
Test sample.
Test Sample.
Test Sample.
Negative control – to confirm that Listeria cells were not present
in the food matrix prior to inoculation.

Microtiter plate biofilm assays. Biofilm assays were carried out as described by
(Begley et al., 2009). L. monocytogenes 10403S was grown overnight in 10 mL of BHI broth
at 37 C. Overnight culture were centrifuged at 8,000g x 6 min, the supernatant was discarded
and the cell pellet was re-suspended in ¼ strength Ringers’ solution and samples were re-
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centrifuged. The supernatant was removed and pellets were re-suspended in 10 mL fresh BHI
broth. 100µl of the resulting washed cells was added to 10 mL fresh BHI broth and cells were
mixed by vortexing. 180µL was subsequently transferred into individual wells of a sterile 96
well flat bottom plate (Sarstedt cat no. 82.1581.001). 2µL of CFS from gut-derived strains
prepared as previously described in chapter 1 was added to specific wells. Plates were sealed
with parafilm in order to prevent evaporation and incubated statically at 37 C for 18 hr. All
experiments were performed in triplicate using three biological repeats. Sterile broth alone was
used as a negative control. Listeria alone was used as a positive control. After the incubation
step, the contents of wells were removed and each well was washed three times with 200µL of
sterile water to remove unattached or loosely bound cells. The plate was allowed to dry adjacent
to a Bunsen burner for 30 min after which attached cells were stained by the addition of 200µL
of a 1% aqueous crystal violet solution (Sigma Aldrich) for 45 min. The stain was removed
and wells were washed three times with sterile water. Bound stain was re-solubilized in 200µL
96% ethanol and OD595 nm was determined.
Examination of biofilm formation by L. monocytogenes on stainless steel. An
assay for examining the formation of Listeria biofilm on stainless steel was devised. Stainless
steel coupons (2 cm x 2 cm) were obtained from Dr. Hugh O` Donnell from the Department of
Biomedical Engineering in CIT. The coupons were autoclaved in freshly prepared phosphate
buffer pH4, they were then scraped with sterile cotton swabs and 100% ethanol in order to
remove bacterial from the surface of the coupons, they were then were left to dry by the Bunsen
flame. The coupons were subsequently aseptically placed into individual wells of a 6 well
microliter plate (Starstedt cat no. 83.1839) and 50 mL Falcon tubes. 3mL of fresh BHI broth
inoculated (1%) with washed Listeria cells was added to each well of the 6 well plates and 15
mL of fresh BHI broth that was inoculated (1%) with washed Listeria cells was added to each
Falcon tubes. Each experiment was set up in triplicate and incubated at 37 C (as described
below) for 16 hr and biofilm were examined. One plate and one set of tubes were incubated
statically and one plate and one tube were incubated in a shaking incubator at 100 rpm. Biofilms
were measured in all plates and tubes by staining with crystal violet and de-colorization with
96% ethanol and measuring absorbance at 595 nm. Finally one plate and one tube were
incubated statically. One plate and one tube were incubated in a shaking incubator at 100 rpm.
Biofilm were measured in the last set of samples by sonication of the coupons and performing
plate counts. The sonication method described by Bjerkan et al. (2009) was followed. In
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summary, after the washing step the coupons were submerged in 5ml of sterile ¼ strength
Ringers solution and were sonicated in a Soniprep 150 ultrasonic disintegrator (MSE, UK Ltd)
for 1 minute on each side (in order to remove the biofilm formed by Listeria cells bound to the
surface of the coupons) 100 L of the resulting cell suspension was then serially diluted in
900 L of sterile ¼ strength Ringers solution. 10 L spots of each dilution and the neat undiluted
samples were spotted onto fresh LSA agar and were incubated at 37 C for 48hr.
Examination of the effects of gut-derived antimicrobials on Listeria’s biofilm
formation on stainless steel coupons. Sterile stainless steel coupons were aseptically placed
into individual wells of a 6 well microliter plate. The coupons were then covered with 3 mL of
fresh BHI broth that had been seeded with 1% inoculum of washed L. monocytogenes 10403S
cells. Various aliquots (10 L, 30 L and 100 L) of CFS or WCE from isolate 15, isolate 43 or
enterocin A producing E. faecium DPC6482 were added to separate wells. The contents of each
well was mixed by pipetting the well contents up and down a few times as well as swirling of
the plate manually. The plates were then incubated at 37 C for 16 hr. Following the incubation,
the stainless steel coupons were removed from the wells and were washed three times in 5 mL
phosphate buffer saline (PBS). The coupons were then left to dry for 30 min. The coupons were
subsequently stained with 1% crystal violet solution for 45 min and were then washed three
times with sterile PBS and dried at room temperature for 30 min. The stain bound to the biofilm
was then decolorized by application of 5 mL 96% ethanol and the biofilm was quantified by
measuring its absorbance at 595 nm.
Antimicrobial peptide purification. Bacteriocin purification was performed in
accordance to the method described by Aspri et al. (2017) with slight modifications. Pure
cultures of gut-derived isolates 15 and 43 were grown on BHI agar and then aerobically grown
overnight in 5 mL of BHI broth at 37 C, the culture was then transferred to 30 mL of BHI broth
and incubated for 8 hr at 37 C, following the incubation the culture was transferred to 2 L of
fresh BHI broth and was incubated overnight at 37 C. The resulting cultures were then
centrifuged at 8,280 g for 20 min. The cell pellets retained and re-suspended in 250 mL of 70%
isopropanol 0.1% TFA. The cell suspensions were then stirred at room temperature for 3-4 hr
and were centrifuged as described above; the supernatants were retained for further analysis.
The IPA was eliminated from the supernatant using rotary evaporation (Buchi, R-300, Flawil,
Switzerland). The samples were then passed through a 12 mL, 2 g Strata–E C18 SPE column
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(Phenomenex, Cheshire, UK) pre-equilibrated with methanol and water. The column was
washed with 12 mL 30% ethanol and then 20 mL 70% isopropanol 0.1 TFA (IPA). Well
diffusion assays were carried out with L. innocua DPC 3572 as the indicator strain to show the
activity of the sample at different stages of purification. Mass spectrophotometer analysis of
each sample was then carried out with Axima TOF 2 (Shimadzu Biotech, Manchester, UK) mass
spectrophotometer. Each sample was then concentrated and passed through an analytical
Proteo Jupiter (4.6 x 250 mm, 90Å, 4µ) RP-HPLC column (Phenomenex, Cheshire, UK) with
a 25-55% acetonitrile 0.1% TFA and 90% acetonitrile 0.1% TFA (buffer B). The fractions of
the eluent were collected at 1-min intervals and were monitored at 214 nm. The anti-Listeria
activity of the fractions was assayed by carrying out a well diffusion assay on L. innocua DPC
3572 indicator plates. The molecular masses of the active fractions were analyzed on a mass
spectophotometer and were then lyophilized with a Genevac HT4X lylophiliser (Genevac Ltd,
Ipswich, England).

Fig.1 A schematic representation of peptide purification methods. (This figure was obtained
from Dr. Máire Begley).

Assessment of the anti-Listeria activity of partially purified peptides.
Lyophilized preparations of anti-Listeria peptides were weighed and re-suspended in 1 mL
sterile water (the final concentration was 18.1 mg/mL for gut- derived isolate 15 and
7.91mg/mL for gut derived isolate 43). Well diffusion assays were carried out with various
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Listeria strains. Briefly fresh BHI agar was made, once the temperature of the molten agar was
~ 50°C aliquots of agar were seeded with 1% inoculums of overnight cultures of

L.

monocytogenes 10403S, L. monocytogenes L028, L. monocytogenes EGDe, L. monocytogenes
F2356 and L. innocua 13568t grown in BHI broth .The agar was then left to dry and 5 mm
wells were cut in each plate. 10 L aliquots of antimicrobial preparations were then added to
wells and plates were incubated at 37 C for 16 hr following the incubation plates were
examined for zones of inhibition.
Arbitrary Units (AU)/mL of activity against L. monocytogenes 10403S.
Lyophilized preps were re-suspended in sterile water and dilutions were made using sterile
water (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024 and 1:2048). 10 L aliquots
of each dilution were then added to individual wells of a BHI agar plate that was seeded with
1% L. monocytogenes 10403S. Plates were incubated at 37 C for 16 hr after which they were
examined for zones of inhibition and the AU/ mL were calculated by multiplying the dilution
factor of the last clear zone of inhibition by reciprocal of 20.
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RESULTS
Investigation of the ability of gut-derived isolates to inhibit Listeria in a co-culture
model broth system. The ability of 14 of the short-listed gut derived- isolates identified as
Enterococcus spp. to inhibit Listeria when co-cultured in broth was examined as outlined in
the Materials and Methods section. A positive control, i.e., a known enterocin A producer, E.
faecium DPC6482, from our culture collection was included for comparison purposes. A coculture assay was carried out in a model broth system. A variety of results were obtained in the
assay (Fig.2). It should be noted that the initial L. monocytogenes inoculum at T=0 was
established as Log 7 CFU/mL. Following 8 hr incubation, the number of Listeria cells in the
negative control showed a ~2 log increase in the number of cells. The positive control brought
about a decrease in the number of Listeria cells by ~ 3 log following 8 hr incubation. A number
of isolates showed a reduction in the number of Listeria cells; co-culture with isolates 54, 43
and 15 all demonstrated a reduction by ~3 log. Isolates 29, 52, 72 and 38 showed a ~2.5 log, ~
2 log, ~ 1 log and ~0.5 log decrease in the number of Listeria cells, respectively. Isolates 4, 12,
18,20, 40 and 57 all showed a slight increase in the numbers of Listeria, but the counts were
lower than the –ve control. Based on these results and the findings presented in Chapter 1, two
isolates (15 and 43) were selected for further investigation.
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Fig.2 Inhibition of L. monocytogenes 10403S by a known enterocin A producer E. faecium
DPC 6482 and 14 gut-derived isolates in a broth-based co-culture experiments. The bar chart
shows L. monocytogenes 10403S counts in each experiential set up at T8 hr. (-ve) control =
L. monocytogenes 10403S alone. (+ve) control = L. monocytogenes 10403S + enterocin A
producing E. faecium DPC 6482. The red line indicates the initial number of L. monocytogenes
10403S (i.e. counts at T0 =Log 7 CFU/mL).
Investigation of antimicrobial activity of CFS and WCE from gut isolates 15
and 43 in model food trials.

A
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CFS
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Fig.3 A representative figure showing the zones of inhibition obtained in a well diffusion assay
carried out in BHI agar seeded with 1% L. monocytogenes 10403S showing the difference in
activity displayed by whole cell extract (WCE) vs. cell free supernatant (CFS) of gut derived
isolates (A) 15 and (B) 43. 70% IPA 0.1% TFA was added to the wells as a negative control.
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Fig. 3 visualizes the difference in the anti- Listeria activity observed in the CFS vs.
WCE from the selected gut- derived isolates. A noticeable difference can be seen in the size
and the appearance of the zones when comparing WCE vs. CFS. The results obtained for both
gut- derived isolate 15 and 43 were the same; the zone of inhibition obtained for WCE was
recorded as 15mm while the one obtained for CFS was 11mm. The negative control shows that
IPA used in extraction of the WCE does not contribute to the antagonistic activity of the extract.
The CFS and WCE from isolates 15 and 43 as well as a known enterocin A
producer E. faecuim DPC 6482 were added to various dairy foods otlined in the materials and
methods section. Listeria counts were determined at various time points with a view of
examination of the anti- Listeria acitivty of the isolated enterococcal antimicrobials in food
matrices. A food trial performed in a model cheddar homogenate (Fig.4 –A) shows that
treatment with 100 L of CFS from gut derived isolates 15 and 43 as well as an enterocin A
producing strain did not inhibit the growth of Listeria in the cheddar model. However, the
results do show that Listeria growth was hindered in comparison to the negative control with
no antimicrobial agent present. The trial carried out in a model soft cheese homogenate (Fig.3B) shows a reduction of growth by ~0.3 log in samples treated with isolate 15 and the enterocin
A producer, while Listeria present in the sample did not grow following the treatment with
CFS from isolate 43. The trial carried out in a model natural yogurt homogenate (Fig.4-C)
shows that treatment CFS from gut derived isolates 15 and 43 reduced the number of Listeria
cells in the sample by ~0.5 log and ~0.6 log, respectively, while the reduction observed by the
enterocin A producer was ~0.4 log. For the model feta and brie (Fig.4-D, Fig.4-E), the effect
of the treatment with CFS from gut derived isolates as well as the enterocin A producing strain
could not be determined as the initial number of Listeria added to the samples was reduced in
all samples, including the negative controls, suggesting that Listeria was inhibited by the
constituents of the food products. Fig.4-F shows the results obtained in a cottage cheese
homogenate. Here the treatment with CFS from gut-derived isolate 43 and the enterocin Aproducing strain inhibited the growth of Listeria keeping the cell numbers the same as the
initial inoculum following a 3 hr incubation from the initial inoculum levels while CFS from
gut-derived isolate15 showed to have no inhibitory effect.

85

Fig.4 Inhibition of L. monocytogenes 10403S by the CFS from a known enterocin A producer
E. faecium DPC6482 and gut derived isolates 15 and 43.The bar charts show L. monocytogenes
10403s counts at T3hr. The red lines indicate the initial Listeria counts at T0hr. Control - dairy
product homogenate inoculated with L. monocytogenes 10403S + 100 L of sterile BHI broth,
which acted as the negative control. Enterocin A producer– dairy product homogenate
inoculated with L. monocytogenes 10403S + 100 L of CFS from E. faecium DPC 6482 which
acted as a positive control. Test samples- dairy product homogenate inoculated with L.
monocytogenes 10403S + 100 L of CFS from gut-derived isolates 15 and 43; (A) cheddar,
(B) soft cheese, (C) natural yogurt, (D) feta, (E) brie, (F) cottage cheese.
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Fig. 5 Inhibition of L. monocytogenes 10403S by the WCE from a known enterocin A producer
E. faecium DPC6482 and gut derived isolates 15 and 43.The bar charts show L. monocytogenes
10403s counts at T3hr. The red line indicates the initial Listeria counts at T0hr. Control - dairy
product homogenate inoculated with L. monocytogenes 10403S + 100 L 70%IPA0.1%TFA,
which acted as a negative control. Enterocin A producer – dairy product homogenate inoculated
with L. monocytogenes 10403S + 100 L of WCE from E. faecium DPC 6482, which acted as
a positive control. Test samples- dairy product homogenate inoculated with L. monocytogenes
10403S + 100 L of WCE from gut-derived isolates 15 and 43; (A) cheddar, (B) soft cheese,
(C) natural yogurt, (D) feta, (E) brie, (F) cottage cheese.

Fig. 5 shows the results obtained when samples were treated with WCE from gutderived isolates. A model cheddar homogenate treated with WCE from gut-derived isolates 15
and 43, as well as the enterocin A producer, can be seen in Fig.5-A. Treatment with WCE from
isolate 15 resulted in a reduction by ~1.5 log, WCE from isolate 43 reduced the number of
Listeria by 0.4 log, and the enterocin A producer brought about a reduction of ~0.5 Log. Fig.5B shows the results obtained in a model soft cheese homogenate. The numbers of Listeria were
decreased by treatment with all test samples; with a reduction by Log ~0.5 log by WCE from
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isolate 15 and a reduction of ~0.4 log by isolate 43. The results acquired from trial in a model
natural yogurt homogenate are presented in Fig.5-C. The numbers of Listeria were decreased
by treatment with WCE from all test samples by ~0.5 log. Fig.5-D shows the results obtained
in the feta homogenate model. The reduction in the number of Listeria observed in the sample
treated with WCE isolate 15 and the positive control was ~0.6 log and ~0.3 log by isolate 43.
The results obtained from the trial carried out in a model brie homogenate seen in Fig.5-E
suggest that the treatment with WCE had a minimal to no effect on Listeria numbers. It can
also be concluded that treatment of the cottage cheese seen in Fig.5-F had no impact on the
numbers of Listeria present in the sample.
Microtiter biofilm assay. A biofilm assay was carried out in order to investigate
whether the antimicrobials showing antagonistic activity against Listeria isolated in this study
have anti- biofilm properties. The results obtained in the microtiter biofilm assay carried out
with CFS from 14 shortlisted gut-derived isolates identified as Enterococcus are summarized
in Table 2 and show that 3 (21%) of the tested isolates contributed to biofilm reduction greater
than 75% when comparing it directly to the negative control. Additional 5 (36%) of the tested
isolates have showed biofilm reduction between 50-75% in comparison the negative control, 3
(21%) of the tested isolates have shown biofilm reduction between 20-50%, while 1 (7%) of
the tested isolates showed a biofilm reduction < 10%. Additionally 2 of the tested isolates
(14%) contributed to an increase in biofilm formation. Overall the assay has demonstrated the
ability of the CFS extract from selected gut derived isolates to prevent biofilm formation on
plastic surfaces.
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Table 2. Summarised results obtained in the microtiter biofilm assays where 180 L of BHI
broth was inoculated with washed L. monocytogenes 10403S cells and 20 L of CFS from
selected gut-derived isolates, incubated overnight at 37° C for 18 hr, washed, stained with 1%
aqueous crystal violet and quantified at 595nm. The % values in the table show the % increase
(+) or decrease (-) in OD595nm compared to the OD595nm obtained for the control (i.e. L.
monocytogenes 10403S in broth alone). Biofilm assays were performed in triplicate with three
biological repeats and repeated twice (i.e. a total of 9 biological repeats. The results represented
in the Table are averages of one set of biological repeats but are representative of all 3
experiments).
Isolate ID

Effect on biofilm formation

4

- 94.69%

12

- 53.84%

15

- 69.13%

18

- 5.53%

20

- 27.47%

29

- 81.94%

38

+ 41.57%

40

- 68.45%

43

- 20.59%

48

- 70.97%

52

- 53.17%

54

- 90%

57

- 37.50%

72

+ 7.98%

Assessment of biofilm formation by Listeria on stainless steel coupons and
examination of anti-biofilm properties of CFS and WCE from gut-derived isolates 15 and
43. Various methods were assessed for examining biofilm formation by Listeria on stainless
steel coupons. The most reproducible results were obtained when experiments were performed
under static incubation conditions after which biofilm were stained with crystal violet and the
biofilm quantified by decolorizing with ethanol and OD measured. Representative images of
biofilm experiments and corresponding quantification of results can be seen in Fig.6. It was
observed that Listeria could form biofilm on the coupons and biofilm formation was prevented
when increasing amounts of WCE from selected gut-derived isolates.
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A

B

Fig6. (A) Biofilm formation by Listeria on stainless steel coupons. Stainless steel coupons
were covered in fresh BHI broth seeded with 1% of washed L. monocytogenes 10403S cells
+/- WCE extract from gut derived isolate 43. (1) Control: Listeria + 100 L 70% IPA0.1%TFA,
(2) Listeria + 10 L WCE from gut-derived isolate 43, (3) Listeria + 30 L WCE from gutderived isolate 43 (4) Listeria + 100 L WCE from gut-derived isolate 43. (B) A representative
chart displaying a reduction in biofilm formed by Listeria on stainless steel (2cm x 2cm)
coupons. Stainless steel coupons were covered in fresh BHI broth seeded with 1% of washed
L. monocytogenes 10403S cells. The resulting cultures underwent treatment with WCE from
gut-derived isolates 15 and 43. (-) Control =70% IPA0.1%TFA added to the culture. Test
samples = WCE from gut-derived isolates 15, 43 or enterocin A producing strain were added
to the culture in a 100 L, 30 L or 10 L volume.

Fig.6-A shows biofilm formation visualized with 1% crystal violet stain. As seen in
the image a strong biofilm was produced by the negative control containing untreated Listeria
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culture visible in row (1). Row (2) shows biofilm formed following treatment with 10 L of
the WCE from isolate 43, here a small difference can be seen. Row (3) represents biofilm
formation following a treatment with 30 L of WCE from isolate 43 a notable difference can
be seen here. Row (4) shows biofilm treated with 100 L of WCE of isolate 43, here barely
any biofilm can be seen. The results of the stainless steel biofilm assay are represented in Fig.
6-B as can be seen the results correspond to the visual representation of the data in Fig.5-A.
Again showing that the reduction of biofilm formed on stainless steel increases with the volume
of added WCE. Based on the results of this assay it can be concluded that the WCA of gut derived isolate 43 causes most biofilm reduction.
1.2

Absorbance at 595 nm

1
0.8
0.6
0.4
0.2
0
(-) control

Ent A producer

Isolate 15

Isolate 43

Fig.7 Biofilm assays using stainless steel (2cm x 2cm) coupons. Stainless steel coupons were
covered in fresh BHI broth seeded with 1% of washed L. monocytogenes 10403S cells and
100 L CFS from gut-derived isolates 15 and 43, (-) Control =100 L of sterile BHI broth added
to the culture, no CFS from gut- derived strain added
As seen in Fig.7the assay was also carried out with addition of 100 L of CFS
from isolates 15, 43 a and an enterocin A producing strain. The results obtained from this
experiment showed that all three test samples have the ability to reduce biofilm by ~70%.
Partial purification of the antimicrobial peptides produced by gut-derived
isolates 15 and 43. Efforts focused on purifying the antimicrobial peptide(s) produced by
isolates 15 and 43 from whole cell extracts, as the agar well diffusion assay shown in Fig.3
suggested that the antimicrobial produced by the strains may be primarily cell associated. A
combination of column chromatograph and RP-HPLC was used. The anti-Listeria activity at
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each stage of the purification process was assessed by agar well diffusion assays. Mass
spectrophotometry was performed at various stages in order to determine the masses of any
peptides present. Previous experiments outlined in chapter 1 suggested that isolates 15 and 43
potentially produce enterocin A. This was confirmed by peptide purification. Data collected
during various steps of the purification process can is represented in Fig.8 and Fig 9. One of
the first steps of the purification was the separation of the CFS from the cells this was carried
out in accordance to the materials and methods section, following the initial centrifugation step
the cells were re-suspended in 70% isopropanol 0.1% TFA the cells were then shaken for 3-4
hours and centrifuged again, the resulting supernatant referred to as WCE was retained and
isopropanol was removed from it using a rotary evaporator, the concentrate was then passed
through Starta – C18 column, the column was then washed with 30% Ethanol and the bound
peptide was then eluted with 70% isopropanol. During each step fractions were collected in
order to show that no activity was lost at any of the stages. Fig.8-A and Fig. 9-A show results
of a well diffusion assay carried out in a L. innocua DPC3572 indicator plate showing that no
activity was lost during the extraction of the antimicrobial peptides from gut-derived isolates
15 and 43, respectively. The first collected fraction (1) represented the WCE extracted from
the cells as can be seen in both figure the fraction has showed activity. This was an expected
result as at this stage the active antimicrobial peptide was stripped off the cell surface and was
suspended in the resulting WCEs. The WCE was then passed through the column. At this stage
the active peptide was expected to bind to the column. As seen in (2) no activity was detected
in the WCE flow through, meaning that all active peptide was indeed bound to the column at
that stage. The next stage involved a washing step with 30% ethanol in order to remove any
unbound peptides and other contaminants, a fraction of the flow through has been collected
and is activity was checked in the well diffusion assay (3) once again no activity was observed,
which means that all the active peptide remained bound to the column at this stage and no
activity was lost. The final stage of the column chromatography was elution with 70%
isopropanol, at this stage the peptide bound to the column should be eluted; therefore activity
should be seen in the fraction collected at this step, which can be seen in well labelled (4). The
eluted peptide was then analyzed using a mass spectrophotometer in order to determine if
masses of any known bacteriocins could be identified. The mass chromatograms showing
results obtained from the analysis of the 70% isopropanol eluent obtained following column
chromatography the results from isolates 15 and 43 are displayed in Fig.8-B and Fig.9-B.
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Fig.8 A figure showing various steps of purification of the antimicrobial peptide from gut
derived isolate 15. (A) a well diffusion assay carried out with BHI agar inoculated with 1% L.
innocua DPC3572. 50 L aliquots from various fractions from column chromatography were
added to the wells. (1) Whole cell extract (WCE) from 2 L of overnight gut derived isolate 15
grown in BHI broth. (2) WCE eluted through Starta-E C18 column (3) 30% ethanol wash (4)
70%IPA elution. (B) A mass chromatogram showing the active IPA eluent of an antimicrobial
peptide produced by the gut-derived isolate 15 showing a peak at 4836. 06Da. (C) A mass
chromatogram showing the active fraction from gut-derived isolate 15 collected during RPHPLC purification showing a peak at 4832 Da.
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Fig.9 A figure showing various steps of purification of the antimicrobial peptide from gut
derived isolate 43. (A) as well diffusion assay carried out with BHI agar inoculated with 1% L.
innocua. 50 L aliquots from various fractions of column chromatography peptide purification
were added to the wells. (1) Whole cell extract (WCE) from 2 L of overnight gut derived isolate
43 grown in BHI broth. (2) WCE eluted through Starta-E C18 column (3) 30% ethanol wash
(4) 70%IPA elution. (B) A mass chromatogram showing the active IPA eluent of an
antimicrobial peptide produced by the gut derived isolate 43 showing a peak at 4838.01 Da.
(C) analysis showing the active fraction from gut-derived isolate 43 collected during RP-HPLC
purification showing a peak at 4838.82 Da.

The mass chromatogram presented in Fig. 8-B displays a peak at 4836.06 Da,
which is a mass relatively similar to that of enterocin A (4832.61 Da). Similar findings were
obtained following mass spectra analysis of the active eluent from isolate 43 Fig. 9-B here a
peak at 4838.01 Da was observed, again showing a mass very close to that expected of
enterocin A. Due to the fact that the mass spectra readings have indicated peaks showing
masses close to that of enterocin A the active 70% isopropanol eluents from isolates 15 and 43
were then passed through a RP-HPLC column with fractions collected at 1 min intervals. Each
resulting fraction was when examined for anti-Listeria activity in a well diffusion assay with
an L. innocua DPC3572 indicator plate (data not shown) in both samples activity was observed
in fractions 24-26, with highest activity observed in fraction 25 meaning that the active peptide
came off the column in those fractions. Based on the results obtained in the well diffusion assay
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fraction 25 was chosen from both isolates and were analyzed on the mass spectra seen in Fig8C and Fig.9-C. The mass chromatogram shows a peak at 4832.87 Da for the antimicrobial
isolated from gut derived isolate 15 and 4838.82 Da for the antimicrobial isolated from gut
derived isolated 43. The masses of the isolated antimicrobials suggest that their identities are
enterocin A with a mass of 4832.61 Da.

Determination of activity of the partially purified antimicrobial from
shortlisted gut isolates against various Listeria indicator strains and AU/ mL arbitrary
units of activity. The anti–Listeria activity of the antimicrobial preparation was confirmed
against a number of Listeria strains including; L. monocytogenes EGDe, L. monocytogenes
L028, L. monocytogenes 2365, L. monocytogenes 10403 and L. innocua in a well diffusion
assay. A two-fold dilution-well diffusion/ critical dilution well diffusion assay was carried out
in order to investigate the Arbitrary Units (AU) of the purified bacteriocins. The AU/mL are
standard units used to measure the activity of antimicrobial agents such as bacteriocins. As can
be seen in Fig. 10-A and Fig.10-B both preps demonstrated activity against all tested strains
of Listeria. The results obtained in are in agreement with the previous findings (chapter 1). The
results show that the partially purified peptide from isolate 15 shows antagonistic activity
against L. monocytogenes 10403S with a visible zone of inhibition when diluted a by a dilution
factor of 1:256 the results obtained can be seen in Fig. 10-C The AU/mL were calculated to be
5120 AU/mL. Similar results were observed when measuring the AU/mL units of the purified
peptide from isolate 43, here once again last clear zone of inhibition was noted in sample
diluted by a factor of 1: 256, again resulting with the AU/mL units to be calculated as 5120
AU/mL as seen in Fig.10-D
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Fig. 10 Results of a well diffusion assay carried out with crude antimicrobial preparations
from (A) gut-derived isolate 15 and (B) isolate 43. The lyophilised peptide was re-suspended
in 1 mL of sterile water resulting in a final concentration of 18.1 mg/mL for isolate 15 and
7.91mg/mL for isolate 43. 10 L was added to the wells and plates were incubated overnight at
37° C. The indicators used were (1) L. monocytogenes EGDe (2) L. monocytogenes L028 (3)
L. monocytogenes F2365 (4) L. monocytogenes 10403S and (5) L. innocua. Panels (C) and (D)
show a well diffusion showing the anti-Listeria effect of the crude antimicrobial prep from gutderived isolate 15 seen in panel (C) and gut- derived isolate 43 seen in panel (D). 5 mm wells
cut in BHI agar seeded with 1% L. monocytogenes 10403S inoculum were filled with 10 L
aliquots of the diluted antimicrobial preparations and incubated at 37° C overnight.
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DISCUSSION
Investigation of the ability of gut-derived isolates to inhibit Listeria in a coculture model broth system. Due to the fact that the inhibitory spectrum of bacteriocins
frequently includes common foodborne pathogenic bacteria, there is growing interest in their
application as natural food additives (Vuyst, 2014). The potential of the application of enterocins
as food additives or their in situ production during food fermentation have been investigated by
(Leroy et al. 2003). The results obtained in the current study have demonstrated that the
antimicrobial agents produced by Enterococcus isolated from the human gut have the ability to
reduce the growth of Listeria in a co-culture assay by up to 3 log CFU/mL following an 8 hr
incubation in BHI broth, thus suggesting their potential application in the food industry. It should
be noted that gut-derived isolates 15, 43 and 54 showing the highest levels of antagonistic
activity have tested positive for cross immunity with enterocin A and enterocin B (chapter 1),
suggesting that the antimicrobials produced by those gut-derived strains may be enterocin A and
B. Fimland et al. (2002) has proposed that cross immunity between class IIa bacteriocin
producers such as E. faecium can occur in situations where the bacteriocins or the immunity
proteins fit to subgroups with related sequences. Suggesting that the antimicrobials produced by
those gut-derived isolates may also be variants or enterocin A and B or may be closely related
to those bacteriocins. The results obtained in the co-culture assay show antagonistic activity
similar to that displayed by the enterocin A producing strain E. faecium DPC 6482. It should be
taken into account that the initial Listeria inoculum was at 107 CFU/ mL, which is much higher
than the usual numbers of Listeria normally isolated from food products, e.g., Moosavy et al.
(2014) has reported to isolate on average 40 CFU/mL of L. monocytogenes in raw milk used for
production of Lighvan cheese. The findings of this study are comparable to findings observed in
studies carried out with LAB found in the literature (Pleasants et al. 2001), where a model coculture broth system of L. monocytogenes and a bacteriocin producing L. sakei 706 showed that
co-culture with a bacteriocin producing strain has detrimental effects on the numbers of Listeria
present in the sample. A study carried out by ( Khay et al. 2013) examined a co- culture of L.
monocytogenes CECT 4032 and E. durans E204 in skimmed milk, the results show that Listeria
population was completely eliminated following a 16 hr incubation with the antimicrobial
producing strain of E. durans. A co-culture in BHI broth treated with CFS from E. durans 4032
showed a rapid a rapid decrease in the number of Listeria cells observed in the first 4 hr after
incubation, similar to that obtained in the current study. The findings of the current study, as
well as evidence found in the literature suggest that the antimicrobials produced by LAB, namely
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Enterococcus spp. have a protective potential, which may be utilized in foods susceptible to
contamination with Listeria.
Investigation of antimicrobial activity of CFS and WCE from gut isolates 15
and 43 examined in model food trials. Dairy based foods especially semi-hard and soft cheeses
are believed to be some of the most significant at-risk products associated with outbreaks of
foodborne listeriosis, and are often recognised as the main channel for human infection with
L.monocytogenes (Hunt et al. 2012; Lahou and Uyttendaele, 2017). Bacteriocins isolated from
LAB often display antagonistic activity against pathogenic bacteria in food (Lewus et al. 1991).
In the current study the effect of CFS and WCE of two gut-derived isolates was investigated in
fermented dairy products. The aim of this experiment was to gain insight if the antimicrobials
produced by the gut-derived isolates have a potential as food preservatives i.e. being used as
potential food additives. It is important to realize that even though an antimicrobial shows
activity in a broth based system that does not mean that one can assume activity in a food system.
Food constituents such as proteins or lipids or the intrinsic properties of the food matrix such as
the aw or the pH of the food material can alter antimicrobial and its effectiveness in the food
product (Davidson et al. 2013).
While variation of results and different rates of Listeria growth have been observed
across different dairy media used, this is not surprising. Relative variation in growth of Listeria
in various cheese media has previously been noted by Lahou & Uyttendaele (2017). The key
findings of the current study show that, when treated with CFS from the gut-derived isolates,
the numbers of Listeria were unaffected, or affected to a minimal degree when growing in
cheddar, feta, brie and cottage cheese. The greatest reduction in the numbers of Listeria was
observed in the natural yogurt homogenate with a 0.6 log CFU/mL reduction following a 3 hr
incubation period. In contrast treatment with WCE from the gut-derived isolates was more
effective, with a reduction of ~1.5 log CFU/mL in the cheddar homogenate. The resutls
obtained in the current study showed that the anti-Listeria activity of the WCE was higher than
that of CFS in most food media. This however was not the case in all food types as the opposite
was observed in the natural yogurt model. A similar experimental approach was undertaken by
Huang et al. (2013), who investigated the use partially purified enterocin RM6 in a cottage
cheese homogenate inoculated with 105 CFU/mL Listeria. This resulted in a reduction in
Listeria numbers by 4 logs in 30 min post treatment and below detectable levels after 26 hr
incubation period. While slight differences in the experimental set-up exist, i.e., the current
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study used a higher initial L. monocytogenes inoculum and the antimicrobials used to treat the
cheese homogenates were at a lower purity level, the results obtained by Huang et al. (2013)
suggest that similar level of antagonistic activity against L. monocytogenes can be expected if
the assay was to be repeated with a semi purified antimicrobial peptide from gut-derived
isolates.
The literature shows a number of approaches in which the anti-Liseria activity of
bacteriocins can be assessed in a dairy foods. Those include; spraying of the bacteriocin
producing strain onto the surface of the cheese as described by Izquierdo et al. (2009) where
bacteriocin producing E. faecium WHE 81 isolated from cheese was sprayed onto the surface
of a Munster cheese at the start of the ripening process. The experiment has shown that while
in some Munster soft cheese samples a number of Listeria cells did survive on the surface of
the cheese it could not grow in the presence of the bacteriocin. The ability of using bacteriocin
producers as starter cultures has also been investigated in great detail Maisnier-Patin et al.
(1992) investigated making of camembert cheese with a nisin producing L. lactis subsp. lactis
starter culture. Liu et al. (2008) has demonstrated the anti- Listeria potential of heterogous
LAB starter culture producing enterocin in cottage cheese manufacture. Cárdenas et al. (2016)
investigated fermented cheese models with a starter culture of bacteriocin producing E. faecium
CECT 8849 isolated from human milk. A study carried out by Leroy et al. (2003) has
investigated the applicability of E. faecium RZS C5 isolated from cheese to be used as a starter
culture in chedar cheese manafacture. Vandera et al. (2017) showed that a cheese isolate E.
faecium KE82 entirely inhibited L. monocytogenes in a raw milk sample following incubation
at 37°C for 6 hr, while the further incubation at 18°C for 66 hr has significantly inactivated the
pathogen. However, there is still a lot of controversy when considering using gut-derived
enterococcal isolates for such applications, thus the activity of the antimicrobials produced by
those isolates can sometimes be harnessed by instead adding a (semi-) purified bacteriocin as
a food ingredient during product manufacture. A recent study Ribeiro et al. (2017) has reported
the effectiveness of a semi-purified enterocin produced by E. faecalis strain isolated from
cheese in reduction of L. monocytogenes in freshly made cheese. The observed reduction was
dose dependent, with the highest dose reducing the numbers of Listeria below levels of
detection. Similarly, Davies et al. (1997) showed that the introduction of nisin to ricotta type
cheese during its production can inhibit the growth of L. monocytogenes for 8 to 10 weeks,
while cheese made without addition of nisin accumulated unsafe levels of Listeria 1-2 weeks
post production. The findings of the current study as well as the evidence found in the literature

99

show that there is a great potential for enterococcal bacteriocins to be used in the food industry
as food preservatives or can be incorporated into the food products as starter cultures.
Examination of the effects of gut-derived antimicrobials on Listeria biofilm
formation on stainless steel coupons L. monocytogenes imposes a serious threat to the food
industry due to its ability to adapt to extreme environmental changes and therefore being able
to withstand numerous hurdles to which it may be exposed during food processing treatment
(Hill et al. 2002). It has been established that despite harsh processing conditions Listeria can
be found in various parts of the dairy processing plant (Waak et al. 2002). Therefore biofilm
formation is of concern to the food industry as it can often cause contamination of the food
being processed on a production line. Biofilms are often formed in areas such as stainless steel
equipment and utensils, processing equipment, conveyer belts as well as storage area surfaces
(Gandhi & Chikindas 2007; de Oliveira et al. 2010). Bacteria growing in a biofilm from often
display higher levels of resistance to unfavorable environments such as heat, sanitizers or
disinfecting agents (Gandhi & Chikindas 2007; Wong 1998). It has been documented that L.
monocytogenes is capable of sustaining growth in a monoculture biofilm as well as being a part
of a mixed culture biofilm. The study by Bremer et al. (2001) has determined a significant
increase in the number of L. monocytogenes cells attached to stainless steel surfaces when
forming a mixed culture biofilm with Flavobacterium when compared to the number of cells
attached to the stainless steel surface when in a monoculture biofilm, it has also been
determined that the survival time of L. monocytogenes has increased significantly in a mixed
culture. This is of concern to the food industry as the possibility of a mixed biofilm formation
are quite high, especially in industrial environments (Bremer et al. 2001; Gandhi & Chikindas
2007). It is also argued that the persistence of L. monocytogenes in food industry premises and
equipment is not a result of strain specific biofilm formation, but a consequence of poor
hygiene in harborage sites (Carpentier & Cerf 2011). Insignificant sanitation and cleaning
procedures especially of food based product contact surfaces, processing environments and the
equipment used has been indicated as one of the major causes contributing to outbreaks of
foodborne diseases especially those associated with L. monocytogenes or Salmonella
(Chmielewski and Frank, 2003). Generally speaking, upon the completion of biofilm formation
the bacterial cells become irreversibly adhered to the surface and often require challenging
chemical or mechanical treatments, which are not always feasible in the food industry setting
(Al-Seraih et al. 2017). A novel natural, sustainable and safe group of anti- biofilm agents can
potentially be established with a view of food safety. Bearing in mind recent research in the
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field of bacteriocins which are promising candidates for such application (Al-Seraih et al.
2017). The biofilm assays carried out in this study show a significant biofilm reduction with
up to 92.42% reduction of biofilm on stainless steel surface when treated with WCE and up to
70% biofilm reduction when threated with CFS from the gut derived isolates. The findings of
the current study are comparable to those described by (Al-Seraih et al. 2017) who examined
the anti-biofilm activity of B3A-B3B enterocin produced by E. faecalis B3A-B3B isolated
from infant faeces.
Partial purification of the antimicrobial peptides produced by gut-derived
isolates 15 and 43. Bacteriocin producing LAB often have complex nutritional needs which
need to be meet in order to confer bacterial growth and bacteriocin production, this causes
difficulties in purification ( Guyonnet et al. 2000; Li et al. 2002). The difficulties are mostly
associated with the fact that bacteriocins are often secreted into the growth medium. In the
current study, the LAB isolates were grown in BHI broth, which is high in peptides of animal
origin. Since the antimicrobial peptides produced by LAB are often produced in low quantities
the peptides of animal origin present in the medium can sometimes be a preventive factor in
the identification of the antimicrobials with mass spectrophotometry methods. This has been
previously reported by Carroilssen-Mackay et al. (1997) and was also the case in the current
study. Because the identification of the antimicrobial peptides has been problematic when the
gut derived- isolates were grown in BHI broth, the activity of the antimicrobials was also
examined when gut-derived isolates were grown in different media (tryptic soy broth (TSB),
tryptone yeast extract (TY) broth and De Man, Rosa and Sharpe (MRS) broth), however
antimicrobial activity was not as high as that observed with BHI broth (data not shown). Mass
spectrophotometric identification of the active peptides present in the CFS was also attempted
when the gut-isolates were grown in clarified BHI broth (data not shown). However, this was
unsuccessful due to a high number of background masses corresponding to the peptides of
animal origin present in medium used in the purifications medium itself.
Due to the fact that bacteriocins belong to a particularly diverse family of peptides,
specific purification protocols must be often designed for each of them (Balciunas et al. 2013).
The current study has encountered a number of problems while trying to purify the
antimicrobials produced by gut-derived isolates. A method previously described by (O'Shea et
al. 2009) has been attempted a number of times (data not shown) and has been unsuccessful.

101

Due to the fact that bacteriocins are secreted into the growth medium, the majority of
bacteriocin purification methodologies begin with a concentration step, where the bacteriocins
are concentrated in the cell free supernatant. The main objective of such procedures is to
decrease the working volume of the antimicrobial being purified rather than to deliver a highly
pure peptide (Guyonnet et al. 2000). A number of protocols have been devised for purification
purposes that involve ammonium sulfate precipitation (Dezwaan et al. 2007; Dündar et al.
2015), absorption-desorption (Yang et al. 1992), and/or organic solvent extraction (Burianek
and Yousef, 2000).
In the current study, the bacteriocins have been extracted with the organic solvent
extraction method and were separated by adsorption onto a C18 column and subsequent RPHPLC as described by (Aspri et al. 2017). The purifications have allowed for detection and
partial purification of enterocin A. However, both gut-derived isolates have tested positive for
both enterocin A and enterocin B in a cross immunity assay carried out with known bacteriocin
producers (see chapter 1). The presence of enterocin A and enterocin B was also detected for
those isolates in a PCR (data not shown).
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CONCLUSIONS
A model broth co-culture experiment was set up with 14 shortlisted gut-derived
isolates identified as Enterococcus. The results obtained in the co-culture experiment have
showed that the numbers of L. monocytogenes were reduced by up to 3 log CFU/mL following
an 8 hour incubation. Based on the results obtained in the co-culture assay two isolates (15 and
43) were chosen for further experimentation. Food trials with CFS and WCE from the selected
isolates were carried out in cheddar cheese, soft cheese, natural yogurt, feta, brie and cottage
cheese. The results of those trials showed a ~ 0.6 log CFU/mL of reduction in the number of
Listeria cells in natural yogurt when treated with CFS. Treatment with WCE has shown to be
more effective than treatment with CFS for most dairy products (with the exception of natural
yogurt) with the highest reduction of ~1.5 log CFU/mL observed in cheddar cheese following
a 3 hr incubation. The anti-biofilm activity of the antimicrobials produced by the gut- derived
isolates was also examined showing a biofilm reduction of 92.42% when treated with WCE
and 70% when treated with CFS. The antimicrobials produced by isolates 15 and 43 have been
partially purified and provisionally identified as enterocin A with masses of 4832 Da and
4838.82 Da respectively. Their activity against L. monocytogenes EGDe, L. monocytogenes
L028, L. monocytogenes F2365, L. monocytogenes 10403S and L. innocua has been confirmed
in a well diffusion assay. The arbitrary units of activity of the partially purified enterocin A has
been calculated to be 5120 AU /mL. The data collected suggest that the antimicrobials isolated
in the current study have a potential for applications as food preservatives or anti-biofilm
agents. However, further experimentation is necessary.
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Thesis Summary
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L. monocytogenes continues to be a major problem to the food industry. Its
versatility in terms of environmental conditions it can survive and its ability to form biofilms
allows it to persist in food and in the food-processing environments. Novel methods are needed
to control L. monocytogenes, which could be used as food preservatives or antimicrobials in
industry settings such as washes or sprays or anti-biofilm agents. Gut bacteria have been shown
to produce antimicrobials and based on the evidence presented in sections 4 and 5 of the
literature review we postulated that gut microbiota may produce novel anti-Listeria
compounds. The aim of this thesis study was to isolate strains with anti- Listeria activity and
characterize them.
To our knowledge this is the first large scale screen for anti-Listeria compounds
from the human gut. The work presented in chapter one focused on isolation and
characterization of gut bacteria with anti-Listeria activity from 23 human faecal banks. A total
of 4,065 colonies were screened in deferred antagonism assays and anti- Listeria activity was
observed for 1,569 colonies. Isolates displaying various levels of anti-Listeria activity were
compared to each other and shortlisted to a total of 59 gut- derived isolates for further
examination on the basis of colony morphology, faecal bank of origin and the level of antiListeria activity. The shortlisted isolates were identified with a combination of MALDI-TOF
analysis and partial 16S rRNA gene sequencing and the vast majority were identified as
Enterococci spp. A total of three isolates were identified as Streptococcus spp. Various assays
were carried out in order characterize the antimicrobials produced by the gut-derived isolates.
Deferred antagonism assays with a variety of indicator strains was carried out to establish the
inhibitory spectrum of activity of the isolates and showed that the antimicrobials produced by
the gut- derived isolates have a narrow spectrum of activity, showing antagonism mostly to
other closely related Gram-positive bacteria such while activity against Gram-negative
organisms was not observed. The nature of the antimicrobials (i.e. cell bound vs. extracellular)
was investigated in well diffusion assays with cell free supernatants (CFS) and whole cell
extracts (WCE) showing that the antimicrobials produced by majority of the gut-derived
isolates secreted their antimicrobials into the growth medium. Based on the data collected it
was determined that there were possibly 17 different strains present amongst the 59 shortlisted
isolates, and those 17 isolates were selected for further investigation. Cross immunity deferred
antagonism assays with gut-derived isolates originating from the same faecal banks showed a
cross immunity in two isolates and allowed for further shortlisting of the gut-derived isolates
to a total of 16. The proteinaceous nature of the antimicrobials was investigated by proteinase
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K deferred antagonism assays and showed that the anti-Listeria activity of 11 out of the 16
shortlisted isolates was likely due to production of an antimicrobial peptide. Further cross
immunity assays with known bacteriocin producers revealed that 4 of the gut-derived isolates
were cross-immune to enterocin A and enterocin B. PCRs confirmed the presence of enterocin
A and B structural genes in the strains.
The key focus of the work presented in chapter two was the further investigation
of the anti-Listeria activity of selected human gut isolates. The anti-Listeria activity of the
isolates was investigated in a model broth co-culture assay and results showed a reduction in
the numbers of Listeria by up to 3 log CFU/ mL after an 8 hr incubation period. Based on
previous studies in our lab we knew that the purification of antimicrobial peptides from
enterococci was challenging, and that the existing purification methods routinely used in our
lab for the purification of other antimicrobial peptides (i.e. the bacteriocins nisin and lacticin
3147) would require optimization. For this reason and given the time restrictions of the current
Masters research project it was decided to focus on two strains in order to optimize purification
methods. Isolates 15 and 43 were chosen due to the fact that biggest zones of inhibition were
produced by those isolates and while the purifications were underway other experiments (food
trials and biofilm assays) were carried out with CFS and WCE in order to optimize those
experiments and obtain preliminary results with crude antimicrobial extracts.
The ability of CFS and WCE prepared from the selected isolates were investigated
for their ability to inhibit L. monocytogenes in cheddar cheese, soft cheese, natural yogurt, feta,
brie and cottage cheese. The results obtained in these food trials have shown a ~0.6 log
CFU/mL reduction in the numbers of Listeria in a natural yogurt homogenate treated with CFS
and ~1.5 log CFU/mL reduction in cheddar cheese homogenate treated with WCE.
Additionally anti-biofilm activity of the extracts was investigated on stainless steel and results
showed a biofilm reduction of 92.42 % following a WCE treatment and a 70% reduction
following treatment with CFS. The antimicrobials of the two selected isolates were then
partially purified and provisionally identified as enterocin A.
The data collected to date shows that the antimicrobials isolated in the current study
have potential applications for novel applications in the food industry such as food
preservatives or as anti-biofilm agents. Future work should focus on sequencing the genomes
of all of the shortlisted gut-derived isolates, the genomes should then be analysed with
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bacteriocin gene cluster mining tools such as BAGEL3 in order to find out what antimicrobial
genes are present and if any of them may encode any novel antimicrobials (as determined by
homology searches and literature searches). If novel antimicrobials were identified their
purification and optimization of purification methods should be prioritized. The antimicrobials
should be then assessed for toxicity and checked for their safety in food applications, if safe
potential food applications as food preservatives, active packaging or cleaning agents should
be investigated as the applications of enterocins of human gut origin into the food industry is a
relatively unexplored area of research.
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